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Abstract

Staphylococcus aureus is a remarkably pathogenic bacterium that is widely prevalent
among the human population. It is the leading agent of skin and soft tissue infections,
and is also responsible for causing an array of severe and life threatening diseases. The
invasiveness of the pathogen, coupled with increasing antibiotic resistance seen for S.
aureus infections, makes this bacterium a prominent public health concern. The
extended pathogenicity of S. aureus is largely due to its repertoire of virulence factors,
which are typically characterized by being bound to the cell wall, or secreted into the
extracellular environment. Previously, our lab identified a leucine aminopeptidase
mutant (pepZ) as being strongly attenuated in virulence for both systemic and localized
models of infection. Importantly, PepZ marked the first intracellular bacterial
aminopeptidase found to be involved in pathogenesis in Gram-positive bacteria. In this
study, we set out to explore the role of the remaining eleven, non-essential,
uncharacterized aminopeptidase enzymes in S. aureus disease causation, and present
two additional aminopeptidase genes, pepT1 and pepT2, which are important for
virulence in both human ex vivo models, and murine in vivo models of disease.
Interestingly, these enzymes do not appear to be necessary for the utilization of free
peptides for cellular nutrition and metabolism, which is a typical characteristic of
aminopeptidases. Transcriptional analysis reveals maximal expression of pepT1 and
pepT2 during early exponential growth phase, while localization mapping demonstrates

vii

that the PepT1 and PepT2 enzymes are found in the bacterial cytoplasm during all
stages of growth. To explore these findings on a global level, an in-depth proteomic
investigation of cleavage properties and cellular substrates identified several proteins as
having significant changes in N-terminal peptide abundance in pepT1 and pepT2
mutant proteomes. We identified a number of putative independent and shared targets
for the PepT1 and PepT2 enzymes that are known to impact cellular fitness and
pathogenesis, including: DnaK, a heat shock protein conserved throughout all
organisms, which functions to help deal with mis-folded and aggregated proteins that
have accumulated as a result of cellular stress; ArlR, the response regulator of the
ArlRS two-component system, which is an important regulator of agglutination and
virulence in S. aureus; and of special interest, ClpC, an ATP-dependent protease
chaperone which is a component of the primary machinery by which protein degradation
occurs in S. aureus. Collectively, our data proves the importance of the PepT
aminopeptidase enzymes in S. aureus pathogenesis, and indicates these enzymes are
likely involved in bacterial stress response and virulence by functioning through the
bioactivation/inactivation of key cellular proteins.

viii

Introduction

Staphylococcus aureus. Staphylococcus aureus is a Gram-positive opportunistic
pathogen, which was first discovered in 1880 in the pus secretions from a knee joint
abscess, by the surgeon Alexander Ogston (1). The bacterium is found to colonize the
skin, anterior nares, and upper respiratory tract of humans and also a wide range of
animals (2-4). It is a non-spore forming member of the Firmicutes, a phyla consisting of
bacteria characterized by a low G+C chromosomal content. S. aureus gets its name
from the yellow-gold colored, cocci shape of its cells, which arrange together to form
grape-like clusters (5, 6). The notable golden pigment of the bacterium is a result of the
membrane-bound carotenoid staphyloxanthin, which is involved in enhancing the
virulence and fitness of the cell by protecting against exogenous stressors and DNA
damage (7, 8). S. aureus is further characterized by being a catalase-positive,
facultative anaerobe, which is capable of complete hemolysis of red blood cells, as well
as surviving significantly hostile environmental conditions (9, 10). Additional analysis of
S. aureus indicates it has a genome size of approximately 2.81Mb, which has a 32.8%
G+C chromosomal content, and contains plasmids, prophages, and multiple
pathogenicity islands (11-13).

Disease Causation of S. aureus. Although there are more than 40 species of
Staphylococcus, Staphylococcus aureus stands alone in its severe disease causation in
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humans.

S.

aureus

is

highly

prevalent

among

humans,

commensally

and

asymptomatically colonizing approximately 20-40% of the adult population (14). Even in
its commensal state, carriers of S. aureus have an increased propensity of developing
an infection, and are key reservoirs for spread of the bacterium amongst individuals.
Unsurprisingly, the most prominent mode of transmission of S. aureus is through
human-human contact via commensally colonized individuals, while direct contact with
contaminated surfaces is likely to play a much smaller, although nonetheless important,
role in transmission (15, 16). The bacterium’s preferred niche consists of the skin and
mucous membranes of humans, and, despite being an effective barrier against bacterial
invasion, even minor skin damage or mucosal trauma can easily allow S. aureus to gain
access to underlying tissues or the bloodstream; and cause infections (17). Once inside
the body, it begins to invade host tissues and form a biofilm through attachment to host
extracellular matrix proteins (18). In addition, S. aureus will utilize the bloodstream to
spread to other organs in the host. Although the bloodstream is a notably harsh
environment for bacterial survival due to an abundance of host immune factors, it has
been proposed that S. aureus may actually exploit these factors as a mode of
dissemination. A recent study shows that S. aureus has the ability to survive and
proliferate inside professional phagocytes for several days without affecting viability,
until the bacterium lyses the cell and escapes (19). Thus, S. aureus potentially utilizes
these “mobile cells” as a vessel for dissemination of infection.

Due to the frequent colonization of humans, and the pathogens ease of invasion, S.
aureus is the leading cause of skin and soft tissue infections (20, 21), which include
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abscesses, consisting of pockets of infection which form at the site of injury, impetigo,
which causes pustules and skin sores, and cellulitis, an infection of the underlying
layers of the skin (20, 22). S. aureus is also responsible for causing a plethora of severe
diseases, such as endocarditis, an infection of the inner layer of the heart, toxic shock
syndrome resulting from exposure to large amounts of bacterial toxin, pneumonia, and
osteomyelitis (23). Colonization of medical devices and catheters is also common with
S. aureus infections, and is a result of its ability to form a biofilm within the host (24). In
addition, several host related factors such as immunodeficiency, neutrophil defects, and
the presence of underlying diseases result in a particularly high risk of S. aureus
infection due to a diminished immune response to the pathogen (25).

S. aureus Antibiotic Resistance. Prior to the discovery and deployment of antibiotics,
Staphylococcus aureus related bacteremia had mortality rates of approximately 80%
(26). However, even in the current “antibiotic era”, S. aureus infection is a mounting
concern due to the increasing difficulty in treatment as a result of the pathogens
notorious antibiotic resistance (27, 28). It should be noted that S. aureus is naturally
susceptible to essentially every antibiotic thus far developed, however, resistance is
frequently acquired through horizontal gene transfer, and chromosomal mutation (25). It
was this remarkable antibiotic susceptibility that originally led to the unearthing of the
“wonder drug” penicillin, and it’s application in clinical practice in the 1940’s. However,
less than two years after the introduction of penicillin, S. aureus strains were already
acquiring resistance, and the pathogen had once again become a major problem in
hospital and healthcare settings (22). Within a decade, penicillin resistant S. aureus
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strains had disseminated from hospitals and into the community. It was estimated that
more than 80% of all hospital and community acquired S. aureus isolates were resistant
to penicillin only 20 years after the introduction of the drug (29). Penicillin resistance in
S. aureus is mediated by blaZ, which is a gene encoding β-lactamase (30, 31). When
exposed to penicillin, the bacterium synthesizes β-lactamase, which then renders the
antibiotic inactive by hydrolyzing the β-lactam ring (29, 31).

In 1961, methicillin, a semi-synthetic β-lactamase-resistant penicillin, was introduced to
combat the ever-increasing burden of drug resistance seen with S. aureus infections
(32, 33). The battle was short lived, however, with the rapid emergence of methicillin
resistant S. aureus clones. Methicillin resistance in S. aureus is characterized by a
chromosomal gene, mecA, which encodes a penicillin-binding protein, PBP 2’ (34). PBP
2’ is a membrane-bound protein which shares similar function to serine proteases, and
is responsible for catalyzing the transpeptidation reaction necessary for cross-linking
peptidoglycan chains in the cell membrane (35). The PBP 2’ enzyme is unique in that it
confers resistance to all β-lactam antibiotics, including the cephalosporins, by blocking
antibiotic access to the active site of the enzyme, while still allowing the transpeptidation
reaction to continue (36). The mecA gene is located on a sizeable mobile genetic
element, designated the staphylococcal cassette chromosome SCCmec (37, 38).
Acquisition of SCCmec occurs through lateral gene transfer, however the genetic
mechanisms responsible for this are still largely unknown. S. aureus strains which have
acquired the chromosomally localized mecA gene, and thus have resistance to β-lactam
antibiotics, including the penicillins and the cephalosproins, are termed methicillin-
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resistant Staphylococcus aureus (MRSA) strains. In contrast, S. aureus strains lacking
the mecA gene, which are thus sensitive to these antibiotics, are termed methicillinsensitive Staphylococcus aureus (MSSA) strains (39). This broad resistance of MRSA
strains to the entire class of beta-lactams is unlike the previously described
penicillinase-mediated resistance, which is very narrow in spectrum (25).

With the mounting staphylococcal resistance to methicillin, glycopeptide antibiotics,
including vancomycin, are often the treatment of choice for severe infections caused by
MRSA (40). Vancomycin was originally approved by the US Food and Drug
Administration in 1958; nearly the same time as the introduction of methicillin (41).
However, due to the perceived toxicity and questionable efficacy, vancomycin was only
administered to patients with severe β-lactam allergies, or as a last resort for those who
showed infections resistant to antibiotics previously implemented (42). It wasn’t until the
1980s that the continued appearance of MRSA strains prompted the resurgence of
vancomycin use, due to its characteristic activity against such isolates. The antibiotic
works through a different mechanism than β-lactam antibiotics, and blocks proper cell
wall synthesis and NAM/NAG crosslinking by binding to the terminal D-Ala-D-Ala
moieties of the NAM/NAG peptides, which form the backbone of the cell wall (43). Since
the widespread administration of vancomycin, strains of S. aureus have emerged that
differ in susceptibility to the drug. A vancomycin-intermediate S. aureus (VISA) strain,
characterized by reduced susceptibility to vancomycin, was first reported in Japan in
1997, from the surgical would of an infant (44). The reduced susceptibility evolved due
to selective pressures, and can be attributed to the over prescription of vancomycin to
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treat MRSA infections. Studies have since shown that consecutive point mutations
within central global regulatory genes contribute to the VISA phenotype, which is
predominantly associated with the restructuring of cell wall metabolism (41, 45). These
vancomycin-insensitive strains have a larger amount of synthesized peptidoglycan,
causing the cells to have thicker, irregularly shaped cell walls (46). In addition, there is a
significant decrease in the amount of cross-linking, which exposes D-Ala-D-Ala
residues, causing vancomycin to bind and thus become trapped in the cell wall (29). Not
only does this result in vancomycin insensitivity, but also mediates resistance to other
antibiotics by impairing their ability to reach the cell membrane. The first S. aureus
clinical isolate with high-level, or “true resistance”, to vancomycin (VRSA) was reported
in 2002, in Michigan (47). VRSA strains have acquired the vanA operon, which is
conjugally transferred from Enterococcus species, and permits synthesis of D-Ala-D-Lac
instead of D-Ala-D-Ala (48). The resulting dipeptide has a markedly reduced affinity for
vancomycin, and allows cell wall peptidoglycan assembly to continue. Although only a
few VRSA cases have been reported thus far, the increasing drug resistance seen for
S. aureus infections, coupled with a limited availability of novel treatment methods,
makes this organism a severe concern, and fosters an extreme need for a better
understanding of its pathogenesis.

Hospital and Community Acquired MRSA. Originally, MRSA infections were limited
to acquisition in a hospital or health care environment, largely affecting elderly,
debilitated adults and were thus termed Hospital-associated MRSA (HA-MRSA) (49). It
wasn’t until 1981 that the first Community-associated MRSA (CA-MRSA) infection was
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reported in intravenous drug users in Detroit, shortly followed by 4 CA-MRSA deaths of
children in Minnesota and North Dakota in 1997 (50, 51). Subsequently, in the late
1990s, other healthy community populations were reported as acquiring MRSA
infections, even those with no previous hospital exposure or outlying predisposition for
the acquisition of MRSA (52). Previously, the term ‘MRSA’ simultaneously implied HAMRSA, however, after the emergence of CA-MRSA infections, the Centers for Disease
Control and Prevention (CDC) outlined a criteria to differentiate between HA-MRSA and
CA-MRSA (49). This differentiation was necessary because the epidemiology, clinical
appearance, and microbiologic characteristics of CA-MRSA strains differ substantially
from those associated with hospital settings (21, 52).

CA-MRSA isolates are characterized by increased virulence, and are normally isolated
from patients whom are otherwise healthy individuals (53). Two CA-MRSA clones,
USA300 and USA400, are responsible for the majority of infections; however recently,
USA300 has become the more prevalent isolate (20, 54-56). USA300 is distinct from
other MRSA strains, and is of serious concern due to the severe invasive infections the
strain causes, such as bacteremia, endocarditis, fatal brain abscesses, severe
respiratory infections, joint infections, and complicated skin infections (57-60). In
addition, USA300 is also being increasingly reported as invading hospitals and
healthcare settings and becoming a cause of many HA-MRSA-type infections (53, 61,
62). USA300 also appears to be more easily transmitted than other strains (63), and is
considered to be extraordinarily infectious due to its heightened lethality and clinical
manifestations, which are far worse than any other strain (64, 65).
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S. aureus Virulence Factors. The extended pathogenicity of S. aureus is largely the
result of its repertoire of virulence factors, which allow the bacterium to invade, adhere
to, and disseminate throughout host tissues and the bloodstream. S. aureus is known to
possess a wider variety of virulence mechanisms than any other pathogen, and has
become a model organism for the study of infectious disease and pathogenesis (66).
Virulence determinants of S. aureus include various secreted toxins, hemolysins,
nucleases, proteases, and adhesins (67). Typically, these exoproteins are secreted,
although a number are characterized by being bound to the cell wall (68). The various
types of S. aureus virulence determinants can be placed into two broad categories
based on their function, and locality among the cell: adherence factors, and exoproteins,
which are found attached the bacterial cell wall, or secreted into the extracellular
environment, respectively. Adherence factors, also termed adhesins, mediate the
adherence of S. aureus to a wide range of host cell surfaces and tissues, including host
extracellular matrix proteins (69). Adhesins facilitate bacterial colonization and
dissemination, and are essential to the pathogenic success of S. aureus. A major class
of S. aureus adhesins are covalently anchored to the bacterial cell wall peptidoglycan
via the enzyme sortase, and are termed MSCRAMMs (microbial surface components
recognizing adhesive matrix molecules) (70, 71). There are approximately 30 different
MSCRAMMs expressed by S. aureus; all of which recognize components of the host
extracellular matrix and serum proteins, including collagen, fibronectin, and fibrinogen
(72, 73). Distinctive proteins of the MSCRAMM family include the fibronectin-binding
proteins A and B (FnbpA and FnbpB), the staphylococcal protein A (SpA), clumping
factors A and B (ClfA and ClfB), and the collagen-binding adhesin (69, 74).
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The secretion of exoproteins is a characteristic of nearly all S. aureus strains, and is a
major factor of the bacterium’s superb ability to cause infection. The vast majority of S.
aureus virulence factors are secreted, and include cytolytic toxins such as α-hemolysin
and the Panton-Valentine Leukocidin; exotoxins such TSST-1 and the exfoliative toxins,
which are the causative agents of toxic shock syndrome and staphylococcal scalded
skin syndrome, respectively; and secreted enzymes such as proteases and
staphylokinase (SAK), which activates plasminogen to form plasmin, an enzyme
capable of digesting fibrin clots (75-77). Cytolytic toxins kill target cells by forming large
pores in the plasma membrane, which causes leakage of intracellular contents and
subsequently lyses the cell (78). The S. aureus alpha-toxin, also known as α-hemolysin
(Hla), was the first pore forming β-barrell toxin to be discovered, and is the primary
secreted cytolytic toxin (9). α-hemolysins insert into the lipid bilayer of red blood cells
and form pores of amphiphilic beta-sheets, which not only cause profound cell leakage
and lysis, but also cause secondary cellular reactions due to calcium influx through the
pores (79). PVL is also a β-pore forming toxin, which causes necrotizing pneumonia by
destroying epithelial and mucosal leukocytes, and has been associated with increased
virulence in several CA-MRSA strains (80).

The

Regulation

of

Virulence

Factor

Production.

Staphylococcus

aureus

pathogenicity is a complex process involving various secreted and cell wall associated
virulence determinants, which are expressed in response to environmental cues during
different stages of infection (28, 81, 82). In order to coordinate differential expression of
these factors, S. aureus encodes a series of global regulatory elements such as agr
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(accessory gene regulator), sarA (staphylococcal accessory regulator), sae, sigB, and
arl within its genome (83-86). These global regulators are essential to allow S. aureus to
survive and adapt to harsh environmental conditions within the host, and mount a
successful infection. Several regulatory loci interact, or “network” together to regulate
the expression of a single gene, in order to ensure the gene of interest is only
expressed under the correct conditions. For example, changes in protein expression
during the transition from exponential to post exponential growth phase has been shown
to be coordinately controlled by both the sarA and agr global regulons (82). The agr
locus consists of an operon of four genes, agrDBCA, and is responsible for controlling
the production of the majority of toxins and exoproteins in S. aureus during postexponential growth phase (87). The operon contains two transcripts, RNAII and RNAIII,
which are driven by separate promoters and transcribed in opposite directions. RNAII
comprises the messages for AgrD, AgrB, AgrC, and AgrA, which essentially correspond
to a two-component signaling pathway activated by an auto-inducing peptide (AIP)
ligand that senses and responds to increasing bacterial densities (88, 89). Upon
mounting bacterial densities, AgrA, the response regulator, binds to the two promoter
regions in agr: P2 for RNAII, and P3 for RNAIII (90-92). Once transcribed, the RNAIII
molecule is responsible for regulating the expression of target genes, and also codes for
the δ-lysin toxin (92). Overall, the agr locus is responsible for up-regulating the
expression of exoproteins, while down-regulating the expression of colonization-related
proteins such as adhesins, upon increasing bacterial densities (91). The sarA regulon
promotes the synthesis of several adhesion proteins and toxins, while also encoding
SarA, a 14.5-kDa DNA-binding protein which is proposed to activate biofilm formation,
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and also helps mediate the expression of virulence factors either directly, by binding to
gene promoters such as agr, hla, and spa, or indirectly by interacting with intermediary
protein factors (91, 93, 94). Most importantly, however, sarA is responsible for the
pleiotropic repression of protease activity in S. aureus, in contrast with agr, which
initiates protease expression as previously described (95, 96).

Proteases. Proteases are a class of degradative enzymes responsible for catabolizing
proteins and peptides by hydrolyzing the peptide bonds, which link amino acids together
in polypeptide chains. Proteases are ubiquitous throughout nature, and are essential for
living organisms due to their integral roles in physiological and pathophysiological
processes (97). In bacteria, these diverse enzymes can be localized to the cytoplasm,
cell wall/membrane, and can also be secreted into the extracellular environment. The
enzymatic actions of proteases can be divided into two groups: limited proteolysis, and
unlimited proteolysis. In limited proteolysis, only one, or a limited number of peptide
bonds are broken on a target protein, further leading to the activation or inactivation of
that protein. In unlimited proteolysis, proteins are degraded into their amino acid
constituents in a non-specific fashion (98, 99). Furthermore, proteases are separated
into two groups based on their site of action: exopeptidases, or endopeptidases.
Exopeptidases catalyze the cleavage of the terminal peptide bonds of proteins and
peptides, releasing single amino acids or small peptides, while endopeptidases catalyze
the cleavage of peptide bonds towards the center of proteins, away from their termini.
Proteases can also be classified into four prominent groups based on their active site:
serine proteases, aspartic proteases, cysteine proteases, and metalloproteases (100).

11

S. aureus Proteases. According to MEROPS, a database resource for proteases, the
Staphylococcus aureus genome encodes approximately 165 known proteases to date.
S. aureus is dependent upon these secreted, cytoplasmic, and membrane-bound
proteases for various cellular functions, such as growth, metabolism, protein quality
control, pathogenesis, regulatory, and housekeeping processes (101-104). In addition,
some of these proteases are utilized by S. aureus as a mechanism to control its own
pathogenesis. This occurs when secreted proteases cleave virulence factors in the
extracellular environment in a nonspecific fashion (105). Because S. aureus is cleaving
its own virulence factors, essentially, the result is an overall decreased virulence of the
bacterium. This can be viewed as a system of checks and balances, which prevents S.
aureus from becoming hyper virulent, and killing the host too quickly. S. aureus
proteolytic enzymes have also been shown to self-target biofilm matrix constituents in
an effort to regulate biofilm formation and dispersal (106). As such, the expression of
proteases in S. aureus must be tightly regulated. Since many of the secreted proteolytic
enzymes of S. aureus are toxins, if left unregulated, they can cause adverse toxicity,
and damage the pathogen itself (107).

There are 10 known secreted proteases of S. aureus, which include aureolysin (Aur),
two cysteine proteases (ScpA, SspB), as well as seven serine proteases (SspA (V8),
and SplABCDEF) (104, 108-111). These extracellular proteases have proposed roles in
virulence, as well as biofilm regulation and detachment, and are important to S. aureus
regulation of disease causation (104, 105, 108, 112). However, the four most prominent
proteases secreted by S. aureus are Aur, ScpA, SspB, and the V8 protease, or SspA
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(113). Most notable, the S. aureus metalloprotease aureolysin, is a very effective
complement inhibitor, which functions to prevent phagocytosis and the perpetual killing
of bacteria by neutrophils; and is also responsible for cleaving the principal complement
protein C3 (114). This results in an overall dampening of the host immune response,
which creates a less hostile environment in order for S. aureus to better survive and
cause infection. The cysteine proteases ScpA and SspB, or staphopain A and B,
respectively, have been shown to inhibit biofilm formation of S. aureus (106), with ScpA
particularly capable of biofilm dispersal. The genes encoding SspA and SspB are
cotranscribed, and both proteins must be cleaved in order to form fully functional
enzymes (104, 113). The V8 protease, SspA, is very well characterized, and has been
shown to play a large role in the progression of disease by cleaving surface protein A
and a fibrinogen-binding protein (113, 115, 116).

Aminopeptidases. Aminopeptidases are a class of exopeptidases that catalyze the
cleavage of N-terminal amino acids from proteins and peptides, as opposed to
carboxypeptidases, which act at the C-terminus of polypeptide chains (117). These
enzymes are widely distributed throughout nature, and can be localized to the
cytoplasm, subcellular organelles, as part of membrane components, as well as
secreted into the extracellular environment (118). Currently, more than one hundred
bacterial aminopeptidases have been purified and biochemically studied, while >40
genes encoding aminopeptidases have been cloned and characterized (119). These
diverse enzymes are classified based on their mechanism of catalysis, structure of
active site, as well as substrate specificity (120). In terms of catalysis, they can be
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divided into three groups: metallo-, cysteine-, and serine aminopeptidases, based on
the amino acids present at their active site, and if a metal ion cofactor is required for
catalysis. Further characterization of aminopeptidases can classify them as di-, tri-, or
oligo- peptidases, which is not only dependent upon the number of N-terminal amino
acids being cleaved (two, three, and four, respectively,) but can also be dependent
upon the type of peptide substrates they act upon (dipeptides, tripeptides, and
oligopeptides). Aminopeptidases are known to perform critical cellular functions, with
the best characterized being the methionine aminopeptidase (MAP), which shares
homology throughout a diverse array of organisms, and functions by cleaving N-terminal
methionine from newly synthesized proteins (121-123). The bacterial MAP in E. coli has
been extensively characterized, and is essential for cell growth and survival (124).
Aminopeptidases also play important roles in protein turnover, and are involved in
regulatory functions (120). Protein turnover is important for cellular nutrition and
metabolism by breaking down larger proteins into individual amino acid constituents for
reuse in anabolic processes and pathways. Aminopeptidase N, found in E. coli, is
involved in overall cytosolic protein degradation, and is responsible for the majority of
the aminopeptidase activity in the cell (125). Bacterial aminopeptidases have even been
found to play important roles in the food and dairy industry. For example, Lactococcus
lactis is known for its ability to ferment milk into cheese, and is a staple starter culture of
the food industry. However, L. lactis would not be able to grow in milk if not for its
aminopeptidases, which degrade the milk protein casein into amino acid constituents
the bacterium needs for metabolism (126). Another important aspect of aminopeptidase
function is the integral role they play in bioactivation and inactivation pathways. N-
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terminal cleavage of a protein target by an aminopeptidase can result in the activation of
a formerly inactivated protein precursor, which can then function in various cellular
processes. However, these processes must be tightly controlled within the cell.
Uncontrolled proteolytic activity results in the undesired cleavage of proteins and is
detrimental to normal cellular physiology due to an imbalance in overall cellular
homeostasis and signaling. Proteolytic control is achieved mostly by substrate
specificity. As such, aminopeptidases can be ordered into two sub-groups based on
their substrate specificity: broad or narrow (120). Aminopeptidases with broad substrate
specificity are capable of acting upon a wide variety of protein and peptide targets, while
narrow specificity aminopeptidases target a select group of protein substrates. Because
of their importance, proteases have become an intriguing drug target for antimicrobial
therapeutics.

Of special interest, aminopeptidases have recently been shown to be involved in
pathogenesis. In Fasciola hepatica, aminopeptidases are essential for invasion,
acquisition of nutrients, and evasion of host immune responses (127). Moreover, two
aminopeptidases, a leucine aminopeptidase and aminopeptidase T, were found to be
upregulated in the proteomes of virulent strains of Streptococcus suis (128).
Additionally, in Salmonella typhimurium, the aminopeptidase PepN modulates systemic
infection when performed in a mouse model (129). Typically, virulence-related
aminopeptidases are secreted outside of the cell, as opposed to the vast majority of
characterized intracellular aminopeptidases involved in protein metabolism and
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regulatory functions, establishing that these enzymes are extremely diverse in their
functionality (130).

S. aureus Aminopeptidases. There are thirteen putative aminopeptidase genes found
in Staphylococcus aureus: pepA1, pepA2, pepA3, pepF1, pepF2, pepM, pepP1, pepP2,
pepS, pepT1, pepT2, pepV, and pepZ (Shaw, unpublished observation), however, only
one has been extensively characterized to date. LAP/PepZ, is a intracellular
aminopeptidase which was first identified by our laboratory and found to be involved in
S. aureus pathogenesis (131, 132). Significantly, PepZ was the first intracellular
bacterial aminopeptidase found to be involved in virulence in Gram-positive bacteria.
PepZ is part of the M17 family of metallo-peptidases, which are established as leucine
aminopeptidases. This family of aminopeptidases has gained a large interest in recent
years due to their involvement in virulence within V. cholera, P. aeruginosa, and S.
typhimurium (129, 133, 134), and potential for vaccine development and therapeutic
intervention in protozoan and parasitic diseases (127, 130). We previously found a pepZ
mutant to be attenuated in virulence in both mouse systemic models of infection and
localized abscess models carried out over a seven day infection period (130). Of
importance, we have also shown that PepZ is not likely involved in nutrition and
metabolism within S. aureus, as the pepZ mutant strain does not contain a growth
defect as compared to the wild-type strain, and is also not required for growth in a
peptide rich environment (130, 132). Additional studies carried out by our lab also
concluded that PepZ has the highest activity against alanine and arginine residues, with
optimal reaction conditions in the presence of MnCl2 at pH 7 (132). Although PepZ is the
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only aminopeptidase to be extensively characterized in S. aureus, the function of two
other aminopeptidases, PepM and PepS, can be moderately elucidated. The activity of
PepM can be hypothesized, based on homology, to catalyze the cleavage of the Nterminal methionine found on all nascent proteins (135-137). It is believed that the pepM
gene is necessary to cell survival, from a number of studies assessing the essential
gene content of S. aureus (138, 139). In addition, the crystal structure of the metalloaminopeptidase PepS from S. aureus has been elucidated, and previous studies
suggest its physiological importance in bacterial survival (140, 141). Furthermore, an
antisense RNA mutagenesis screen against AmpS/PepS from S. aureus was shown to
cause a growth defect, and suggested PepS is involved in peptidoglycan metabolism
(140-142).

Project Aim. Previous studies have revealed the tremendous importance of both
intracellular and extracellular bacterial aminopeptidases. These enzymes have been
shown to have a remarkably dynamic range of functions, varying from cellular nutrition
and metabolism, protein degradation and turnover, cellular regulation, and are even
involved in virulence. However, with the exception of PepZ and PepM, very little is still
known about the aminopeptidases of S. aureus. Therefore, elucidating the pathways in
which aminopeptidases are employed in S. aureus, and the mechanisms by which
these enzymes work, is essential to better understand their role in the cell and potential
contribution to pathogenesis. The remaining eleven uncharacterized aminopeptidases in
S. aureus are PepA1, PepA2, PepA3, PepF1, PepF2, PepP1, PepP2, PepS, PepT1,
PepT2, and PepV. In this study, we aim to further characterize the eleven remaining
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aminopeptidases listed above, and ascertain their role in S. aureus disease causation
and pathogenesis. We plan to accomplish this goal by subjecting S. aureus mutant
strains lacking a functional aminopeptidase gene to a variety of phenotypic,
biochemical, and virulence related assays to determine characteristic differences as
compared to a wild-type strain. Of special interest, we hope to identify other S. aureus
aminopeptidases that are involved in virulence, and determine their mode of action
within the cell. In order to determine the precise mechanisms in which aminopeptidases
are involved in, it is necessary to identify the exact substrate targets these enzymes act
upon. Therefore, we plan to utilize the cutting edge-proteomics tool, N-terminomics,
which will allow us to compare wild-type and aminopeptidase mutant proteomes to
establish differences in protein N-termini. It is possible these analyses could lead to an
identification of potential drug targets and antimicrobial therapies in order to combat
drug resistant S. aureus infection.
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Materials and Methods

Strains, Plasmids, and Primers. All bacterial strains, plasmids, and primers used
during this study are listed in Table 1 and Table 2.

Media and Growth Conditions. All media was prepared by using deionized water
(diH2O) and autoclaved for sterility. Typically, S. aureus and E.coli strains were grown in
100mL volumes (1:2.5 flask/volume ratio) of tryptic soy broth (TSB) or lysogeny broth
(LB) overnight at 37oC shaking at 250 rpm. When necessary, antibiotics were added at
the following concentrations: 100 µg ml-1 ampicillin (E. coli), chloramphenicol 5 µg ml-1
(S. aureus), tetracycline 5 µg ml-1 (S. aureus), erythromycin 5 µg ml-1 (S. aureus),
lincomycin 25 µg ml-1 (S. aureus), spectinomycin 5 µg ml-1 (S. aureus). To obtain a
culture at a specific growth phase, 1mL of overnight culture was subcultured into fresh
media, and synchronized by growing for 3 hours. The optical density (OD600) of the
synchronized culture was then standardized to 0.05, unless otherwise stated, and
allowed to grow until the desired growth phase was reached.

Trypic Soy Broth (TSB)
3% tryptic soy
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Table 1. Strains and Plasmids
Organism
E. coli
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
S. aureus
Plasmid
Plasmid
Plasmid

Strain
DH5α
USA300 HOU
RN4220
SH1000
8325-4
USA300 JE2 pepA1 Tn* Mutant
USA300 JE2 pepA2 Tn* Mutant
USA300 JE2 pepA3 Tn* Mutant
USA300 JE2 pepF1 Tn* Mutant
USA300 JE2 pepF2 Tn* Mutant
USA300 JE2 pepT1 Tn* Mutant
USA300 JE2 pepT2 Tn* Mutant
USA300 JE2 pepP1 Tn* Mutant
USA300 JE2 pepP2 Tn* Mutant
USA300 JE2 pepV Tn* Mutant
USA300 HOU pepS Silent Mutant
USA300 HOU pepA1 Tn* Mutant
USA300 HOU pepA2 Tn* Mutant
USA300 HOU pepA3 Tn* Mutant
USA300 HOU pepF1 Tn* Mutant
USA300 HOU pepF2 Tn* Mutant
USA300 HOU pepT1 Tn* Mutant
USA300 HOU pepT2 Tn* Mutant
USA300 HOU pepP1 Tn* Mutant
USA300 HOU pepP2 Tn* Mutant
USA300 HOU pepV Tn* Mutant
USA300 HOU pepT1 Tn* Mutant
USA300 HOU pepT1/pepT2 Tn* Double Mutant
USA300 HOU pAZ106::pepT1-lacZ pepT1+
USA300 HOU pAZ106::pepT2-lacZ pepT2+
USA300 HOU pMK4::pepT1- His
USA300 HOU pMK4::pepT2- His
USA300 HOU pMK4 empty vector
pAZ106
pMK4 Shuttle vector
pSPC

Markers
N/A
N/A
N/A
N/A
N/A
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
N/A
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Ery/Lin
Spc
Ery/Lin/Spc
Ery/Lin
Ery/Lin
Cm
Cm
Cm
Amp, Ery
Amp, Cm
Cm, Spc

Source
Lab stocks
Kolar, 2011
Kreiswirth, 1983
Horsburgh, 2002
Lab stocks
NARSA
NARSA
NARSA
NARSA
NARSA
NARSA
NARSA
NARSA
NARSA
NARSA
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
Lab stocks
Lab stocks
Lab stocks
Lab stocks

*List of bacterial strains and plasmids used during this study. Antibiotic resistance
markers are: Ery – erythromycin; Lin – lincomycin; Spc – spectinomycin; Cm –
chloramphenicol; Amp – ampicillin. Tn* indicates transposon mutants.
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Table 2. Primer Sequences
Primer

Primer Sequence

Site

Name

OL761

GAC CAT GCA GAG GAT GAT GC

N/A

R pAZ106

OL1036

CCG CGC ACA TTT CCC CGA AA

N/A

R pMK4

OL3106

AAA GGA TCC CAACAGTATCCATATGGC

BamHI

OL3107

TTT TCT AGA GAT TTT GTA TAG GTA G

XbaI

OL3110

AAA GAA TTC TAT AAA ACT TTT AAC TTG AGA CG

N/A

OL3111

TTT CCC GGG TTA GTG GTG GTG GTG GTG TTT
CGA ATG TCG CGC

N/A

OL3112

AAA GAA TTC TTA GAA GTT ACA CTG ATT TCA GG

N/A

OL3113
OL3122
OL3123

TTT CCC GGG TTA GTG GTG GTG GTG GTG GTG
ATT TTC AGC G
AAA TCT AGA CGG TAG ATT TAG AGT TTG GAA
AAG TTG GCG
TTT GGA TCC TAG TAT AAG CAA AAT CAG CAT
TGA AGC GG

N/A
XbaI
BamHI

F pAZ106
pepT2 -lacZ
R pAZ106
pepT2-lacZ
F pMK4
pepT2 - His
R pMK4
pepT2 - His
F pMK4
pepT1 - His
R pMK4
pepT1 - His
F pAZ106
pepT1-lacZ
R pAZ106
pepT1-lacZ

OL3088

TGG TGT GAA TGG TGT TAC CG

F pepV qPCR

OL3089

CAC CTC GAT GTT GAA TTG CTT C

R pepV qPCR

OL3090

TTG GTA TGG GCG TTT CTG G

OL3091

CAC ATG AAG CAC CGT CTT TTG

OL3092

AGGTGATACTGCAACTGGTG

OL3093

TGAAATGTAGCTTCCATCACCAG

OL3094

TGA ATC TTT AAA ACA AGG TGC TAC AG

OL3095

CTG GTT CTA TCA CTC TAC AAT CTG G

F pepT2
qPCR
R pepT2
qPCR
F pepP2
qPCR
R pepP2
qPCR
F pepA1
qPCR
R pepA1
qPCR

*List of primer sequences used during this study. Restriction sties are underlined.
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Top Agar
3% tryptic soy
0.7% agar

Lysogeny Broth (LB)
Tryptone

10 g L-1

NaCl

10 g L-1

Yeast

5 g L-1

Peptide-Rich Media
10% dried skim milk reconstituted in diH2O, and autoclaved for 15 minutes.

Biofilm Media
3% TSB
3% NaCl
0.5% dextrose

Chemically Defined Media

Solution 1
L-Aspartic acid

3g

L-Alanine

2g

L-Arginine

2g
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L-Cystine

1g

Glycine

2g

L-Glutamic acid

3g

L-Histidine

2g

L-Isoleucine

3g

L-Lysine

2g

L-Leucine

3g

L-Methionine

2g

L-Phenylalanine

2g

L-Proline

3g

L-Serine

2g

L-Threonine

3g

L-Tryptophan

2g

L-Tyrosine

2g

L-Valine

3g

Na2HPO4
KH2PO4

140g
60g

Make up to 1400mL with diH2O, and autoclave.

Solution 2
Biotin
D-Pantothenic acid

0.4 mg
8 mg
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Pyridoxal

16 mg

Pyridoxamine diHCl

16 mg

Riboflavin

8 mg

Nicotinic acid

8 mg

Thiamine HCl

8 mg

Make up to 400mL with diH2O, and filter sterilize.

Solution 3
Adenine sulphate

800 mg

Guanine HCl

800 mg

Dissolve in 0.1 M HCl and make up to 2000mL with 0.1 M HCl, then autoclave.

Solution 4
CaCl26H2O

1g

MnSO4

500 mg

FeNH4(SO4)212H2O

600 mg

Dissolve in 0.1 M HCl and make up to 100mL with 0.1 M HCl.

24

Solution 5
Glucose

200 mg

MgSO47H2O

10g

Make up to 2000mL with diH2O, and autoclave.

Amino Acid Limiting Media
Combine the following solutions:
Solution 1

70mL

Solution 3

50mL

Solution 4

1mL

diH2O

759mL

Autoclave the media and cool to 55o, then add the following:

Solution 5

100mL

Solution 2

20mL

Buffers and Solutions. All buffers were prepared using diH2O, autoclaved, and stored
at room temperature, unless otherwise stated.
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Phosphate Buffered Saline (PBS)
0.8% sodium chloride
0.02% potassium chloride
0.14% disodium phosphate
0.02% potassium dihydrogen phosphate
pH 7.4

Phage Buffer
MgSO4

1M

CaCl2

4 mM

NaCl

5.9 g L-1
1 g L-1

Gelatin
Tris-HCl, pH 7.8

50 mM

UDS Buffer
Urea

6M

DTT

5 mM

Tris-HCl, pH 8.0

50 mM

SDS

1%

Polyacrylamide Stacking Gel
Acrylamide
0.5 M Tris-HCl, pH 6.8

650 µl
1.25mL
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10% SDS

50 µl

10% APS

25 µl

TEMED

5 µl

diH2O

3m

Polyacrylamide Separating Gel
Acrylamide

4mL

1.5 M Tris-HCl, pH 8.8

2.5mL

10% SDS

100 µl

10% APS

50 µl

TEMED

10 µl

diH2O

3.3mL

2X Hemolysin Buffer (HA)
10% NaCl

8.5mL

1 M CaCl2

2mL

Make up to 50mL with diH2O.

ABT Buffer
NaCl

100mM

K2HPO4

60mM

KH2PO4

40mM
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Triton X-100

0.1%

ABTN Buffer
0.4 M Na2CO3

0.5mL

ABT

0.5mL

TE Buffer
Tris-HCl, pH 8.0
EDTA

10mM
1mM

Reagents. All reagents used are listed in Table 3.

Bacterial Constructs.

Construction of the pepT-lacZ Reporter Fusion Strains
The pepT1-lacZ reporter fusion strain (Table 1) was constructed using the forward
primer OL3122 and the reverse primer OL3123 (Table 2); to PCR amplify the pepT1
promoter region. The pepT2-lacZ reporter fusion strain (Table 1) was constructed using
the forward primer OL3106, and the reverse primer OL3107 (Table 2); to PCR amplify
the pepT2 promoter region. The resulting fragments were then separately cloned into
the multiple cloning site of the suicide plasmid pAZ106, upstream of the promoterless
lacZ gene. The constructs were confirmed in E.coli, followed by electroporation into
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Table 3. List of Chemical Stressors
Agent

Concentration Stress

Penicillin-G
Agent
Vancomycin
Phosphomycin
Spectinomycin
Ampicillin
Tetracycline
Erythromycin
Lincomycin
Kanamycin
Neomycin
Rifampicin
Chloramphenicol
Oxacillin
Mupirocin
HCL
Phosphoric Acid
TCA
Formic Acid
Acetic Acid
Sulphuric Acid
Nitric Acid
NaCl
Glucose
Sodium Hydroxide
SDS
Triton X-100
Tween-20
N-lauroyl sarcosine
Ethanol
Methanol
Isopropanol
4-methyl methanesulfonate
Ethidium Bromide
Hydrogen Peroxide
Menadione
Pyrogallol
Diamide
Berberine Cl
Peracetic Acid

10mg/ml
Concentration
5mg/ml
4mg/ml
5mg/ml
1mg/ml
5mg/ml
5mg/ml
15mg/ml
50mg/ml
5mg/ml
1.5mg/ml
10mg/ml
10mg/ml
2mg/ml
1M
85%
50%
88%
1%
2M
6M
5M
1M
1M
10%
1%
1%
1M
100%
100%
100%
1M
10mg/ml
30%
1%
50mg/ml
1mg/ml
1mg/ml
4M
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Antibiotic
Stress
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Antibiotic
Acid
Acid
Acid
Acid
Acid
Acid
Acid
Osmotic
Osmotic
Alkaline
Detergent
Detergent
Detergent
Detergent
Alcohol
Alcohol
Alcohol
DNA Damaging
DNA Damaging
Oxidative
Oxidative
Oxidative
Disulfide
Misc.
Misc.

Table 3. (Continued)
	
  
EDTA
10mg/ml
Misc.
DTT
1mM
Misc.
Triclosan
5mg/ml
Misc.
Acridine Orange
1mg/ml
Misc.
Crystal Violet
1%
Misc.
* List of chemical stressors used for lacZ transcriptional and stress profiling
experiments.
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S. aureus strain RN4220, and subsequently transduced into the wild-type strain via
phi11 bacteriophage (Φ11). PCR, and DNA sequencing confirmed both reporter fusion
strains.

Construction of the His Tagged PepT Complement Strains
The pepT1 complement strain (Table 1) was created by using forward primer OL3112,
and the reverse primer OL3113 (Table 2), to PCR amplify a fragment containing the
pepT1 gene and promoter region, followed by additional nucleotides prior to the stop
codon which, once translated, would result in a six histidine tag at the C-terminus of the
protein. Additionally, The pepT2 complement strain (Table 1) was created by using
forward primer OL3110, and the reverse primer OL3111 (Table 2), to PCR amplify a
fragment containing the pepT2 gene and promoter region, followed by additional
nucleotides prior to the stop codon which, once translated, would result in a six histidine
tag at the C-terminus of the protein. The resulting pepT-His6 fragments were separately
cloned into the multiple cloning site of the shuttle vector, pMK4. The constructs were
confirmed in E.coli, followed by electroporation into S. aureus strain RN4220, and
subsequently transduced into the wild-type strain via phi11 bacteriophage (Φ11). PCR,
and DNA sequencing confirmed both complement strains.

Construction of pepT1/pepT2 Double Mutant
The pepT1/pepT1 double mutant strain was created by utilizing the pSPC vector, a
genetic exchange plasmid designed to incorporate alternate antibiotic resistance
markers while subsequently removing the erythromycin cassette found in the bursa
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aurealis transposon (143, 144). As such, the pSPC plasmid was transduced into the
pepT1-Ery marked mutant strain, and the erythromycin resistance cassette was
replaced with spectinomycin resistance, as described previously (145), creating a
pepT1 spectinomycin marked mutant (Table 1). The pepT1-Spc marked mutant was
then confirmed by PCR, and transduced into the pepT2-Ery marked mutant via Φ11.
The double PepT enzyme mutant was selected for based on resistance to
spectinomycin (pepT1) and erythromycin (pepT2), with susceptibility to chloramphenicol
(indicating loss of the pSPC plasmid), and the construct confirmed by PCR and DNA
sequencing.

Virulence Assays.

Survival in Whole Human Blood
Synchronized cultures of wild-type, pepT1, pepT2, pepT1/T2 mutant, as well as their
respective pepT1 and pepT2 complement strains, were grown to exponential growth
phase, and subsequently washed three times in PBS. Cultures were then separately
inoculated into 1mL of whole human blood obtained from Bioreclamation, at an OD600 of
0.05, and incubated for 4h at 37°C with shaking. Samples were withdrawn after 4h, and
plated on TSA to determine percent recovery compared to the inocula.

THP-1 Macrophage Infection
The THP-1 macrophage infection was carried out as described previously (146). As
such, THP-1 human monocytes were grown at 37oC, with 5% CO2, in RPMI medium
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with L-glutamine and 10% fetal bovine serum. Once a desired density was reached, the
macrophages were treated with 80nM PMA (phorbol 12-myristate 13 acetate), to induce
the cells to differentiate and become adherent. After 48h incubation with PMA, the THP1 cells were then seeded into a 96 well microtiter plate at a density of 106 cells/well, and
subsequently infected with 106 CFU/mL of the wild-type, pepT1, pepT2, and pepT1/T2
mutant bacteria. Plates were then centrifuged for 10 minutes at 450 rpm, and
phagocytosis was allowed to progress for 1h at 37°C with 5% CO2. Following
phagocytosis, the cells were washed three times with PBS, and treated with 30 µg mL-1
of gentamycin in culture media for 1h at 37oC with 5% CO2 to kill remaining extracellular
bacteria. To determine the amount of bacteria phagocytized, cells were washed three
times in PBS and treated with 500 µl of 0.5% Triton X 100 in PBS in order to lyse THP-1
macrophages. The cellular lysates were then diluted, and plated on TSA to conclude
percent phagocytized. To determine intracellular survival after 24h, the experiment was
performed as described, however, following treatment with 30 µg mL-1 of gentamycin for
1h, the media was removed, and replaced with media containing 5 µg mL-1 of
gentamycin. Plates were incubated at 37oC with 5% CO2 for an additional 24h, before
treatment with 500 µl of 0.5% Triton X 100 in PBS in order to lyse THP-1 macrophages.
The cellular lysates were then diluted, and plated on TSA to conclude the percent of
intracellular survival.

Co-Infection Models of Systemic Infection
These experiments were carried out as described previously (147). Ten, 6-week-old
female mice were separately co-infected intravenously with 100 µl (a total of 5 x 10!
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CFU/mL) of the wild-type and either the pepT1, pepT2, or pepT1/T2 double mutant
strains in a 1:1 ratio. The infection was allowed to progress for 7 days and the mice
were subsequently euthanized. The kidneys, brain, heart, liver, lungs, and spleen were
harvested, homogenized in 3mL sterile PSB, and serially diluted in PBS. Dilutions were
then plated, in duplicate, on TSA and TSA containing erythromycin, incubated overnight
at 37oC, and bacterial loads determined by calculating CFU/organ.

Biofilm Assay
To assess biofilm formation, overnight cultures of wild-type, SH1000, 8325-4, pepT1,
pepT1 complement, pepT2, pepT2 complement, pepT1/T2, were separately grown, in
triplicate, in biofilm media supplemented with 0.5% dextrose and 3.0% NaCl. 96-well
microtiter plates were then treated with 20% human plasma (5 mL lyophilized plasma
re-suspended in 25 mL carbonate/bicarbonate buffer), and incubated overnight at 4oC.
The following day, the plasma was removed by gentle aspiration, and the cultures
diluted 1:200 in sterile biofilm media. Cultures were then added in 150 µl volumes into
the microtiter plates, and incubated statically at 37oC for 24 hours. Following incubation,
the cultures were aspirated from each well, and the wells subsequently washed three
times with sterile PBS. Biofilms were fixed with 100% ethanol, air dried, and then
stained by adding 200 µl of crystal violet for 2 minutes. Once the crystal violet was
eluted, the wells were again washed three times with sterile PBS, and allowed to dry
overnight. Adding 100% ethanol to the wells and measuring absorbance levels of the
eluted crystal violet, quantified Biofilm growth.
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Hemolysin Assay
Hemolysis experiments were carried out as described previously (148), with the
following modifications. Overnight cultures of wild-type, pepT1, pepT2, and pepT1/T2
mutant strains were measured for OD600, and 1mL aliquots of each was removed, and
placed into a fresh 1.5mL eppendorf, followed by centrifugation at 12,000 rpm for 2
minutes. Equal amounts of the resulting supernatants were mixed with 2X hA buffer in
a 1:1 ratio, and 25 µl of whole human blood was added. Suspensions were mixed gently
by inversion, incubated at 37oC for 40 minutes with agitation, and subsequently
centrifuged at 5,500 rpm for 1 minute. Supernatants were transferred to a 96-well
microtiter plate, and the OD543 measured against a blank of TSB + HA buffer + blood,
and treated as above. Hemolysin units were calculated by the following equation:
(OD543 x 100) / (volume of supernatant (mL) x time (min) x OD600).

Growth and Nutritional Assays.

Growth Analysis in Peptide-Rich Media
Exponentially growing wild-type cells, as well as those for each of the eleven
aminopeptidase mutant strains, were separately inoculated, in triplicate, into 10% skim
milk at a starting OD600 of 0.05, and allowed to grow for 24h at 37°C with shaking.
Samples were taken every hour, and serially diluted in sterile PBS, before plating in
duplicate onto tryptic soy agar (TSA) to assess cell viability by CFU/mL.
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Growth Analysis in Amino-Acid Limiting Chemically Defined Media
Exponentially growing wild-type, pepT1, and pepT2 mutant strains were first grown
overnight on CDM agar, then separately inoculated, in triplicate, into amino acid limiting
CDM media. Cultures were allowed to grow for 7 days at 37oC static, as well as with
shaking. To determine percent survival, samples were taken daily, serially diluted in
sterile PBS, plated in duplicate on TSA, and CFU/mL calculated.

Anaerobic Growth Analysis
Exponentially growing wild-type, pepT1, pepT2, and pepT1/T2 mutant strains were
separately inoculated, in triplicate, in TSB, and allowed to grow for 24h anaerobically.
Cultures were grown in two conditions: 37o C with shaking, as well as 37o C statically.
To determine percent survival, samples were taken at 0h, 3h, 6h, 9h, and 24h, serially
diluted in sterile PBS, plated in duplicate on TSA, and CFU/mL calculated. Plate based
profiling of anaerobic growth was determined using TSA, sheeps blood agar, casein
nutrient agar, nuclease agar, amino acid limiting media, as well as mannitol salt agar
(MSA). Agar plates of each were separately inoculated using three isolated bacterial
colonies from the respective wild-type, pepT1, pepT2, and pepT1/T2 mutant strains,
and grown in parallel under both aerobic and anaerobic conditions at 37oC overnight.

Phenotypic Assays.
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Plate Based Stress Assays
TSA agar plates were overlaid with 5 mL of 0.07% top agar containing equal volumes of
wild-type, pepT1, pepT2, or pepT1/T2 mutant strains at a 1:1000 dilution. Chemical
stressors (Table 3) were subsequently applied in 10µl volumes to 7mm round sterile
Whatman Paper filter disks, which were placed, in triplicate, on the top agar. Plates
were incubated for 24h at 37oC and screened for differences in susceptibility to the
various chemical compounds as compared to the parental strain by measuring zones of
inhibition. The chemical stressors were as follows: penicillin-G, vancomycin,
phosphomycin, spectinomycin, ampicillin, tetracycline, erythromycin, lincomycin,
kanamycin,

neomycin,

rifampicin,

chloramphenicol,

oxacillin,

mupirocin,

HCL,

phosphoric acid, TCA, formic acid, acetic acid, sulphuric acid, nitric acid, NaCl, glucose,
sodium hydroxide, SDS, Triton X-100, Tween-20, N-lauryl sarcosine, ethanol, methanol,
isopropanol, 4-methyl methanesulfonate, ethidium bromide, hydrogen peroxide,
menadione, pyrogallol, diamide, berberine Cl, peracetic acid, EDTA, and DTT.

Triton X-100 Autolysis Assays
Triton X-100 induced autolysis assay was performed, as described previously (149,
150). Exponentially growing cultures of wild-type and pepT1/T2 double mutant strains
were standardized to an OD600 of 0.5, and grown until an OD600 of 1.5 was reached.
Cells were then pelleted, washed three times with sterile PBS, and re-suspended in
sterile PBS containing 1.5% Triton X-100. Cultures were incubated with shaking at
37oC, and the OD600 was measured every 20 minutes for a total of 140 minutes, with a
final measurement taken at 24 hours. Experiments were performed in triplicate and the
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ODs measured in duplicate. Percent survival was determined by the OD600 of each time
point as compared to the initial OD600 measurement.

Membrane Integrity Assays
Synchronized cultures of wild-type, pepT1, and pepT2, mutant strains, were grown to
exponential growth phase, and subsequently washed three times in 5mL of sterile PBS.
A starting sample was taken, serially diluted, and plated in duplicate on TSA, and
CFU/mL calculated. Oleic acid (0.1%) or toluene (1.5%) was then added, and cultures
were allowed to grow for 1h at 37oC with shaking. To determine percent survival,
samples were taken every 15min, and CFU/mL calculated as described.

Oxidative Stress Assay
Synchronized cultures of exponentially growing wild-type, pepT1, and pepT2 mutant
strains were subjected, in triplicate, to the addition of 150mM H2O2, and allowed to
incubate for 10 minutes at room temperature. To determine percent survival, samples
were taken at 0, 5, and 10 minutes, serially diluted in sterile PBS, and plated in
duplicate on TSA, and CFU/mL calculated.

Transcriptional Assays.

Quantitative Real-Time PCR
Cellular mRNA was isolated as described previously (151). To 5mL of synchronized
cultures in exponential growth phase, 5mL of sterile PBS was added. Cells were then
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centrifuged at 4,150 rpm for 10 minutes, the supernatants discarded, and the remaining
bacterial pellets frozen at -80oC overnight. The following day, cells were resuspended in
100 µl of TE buffer, and lysed by bead beating for 40 seconds. Samples were then
treated with 700 µl of β-mercaptoethanol, followed by the addition of 700 µl of RLT
buffer, and lysed by an additional round of bead beating for 40 seconds. The samples
were then centrifuged at 4,150 rpm for 1 minute, and 600 µl of the supernatant
collected, and added to 900 µl of 100% ethanol to provide ideal binding conditions. The
samples were then added to an RNeasy spin column, and treated with 350 µl of RWI.
The columns were washed with 500 µl RPE buffer, and eluted into 50 µl RNase-free
H2O, then treated with DNase at 37oC for 40 minutes. Per the manufacturer’s protocol,
cDNA was then synthesized by utilizing the iScript cDNA kit. Quantitative real-time PCR
was carried out as three independent replicates of 20 µl reactions containing 10 µl syber
(2X master mix), 1 µl forward primer, 1 µl reverse primer, 2 µl cDNA, and 6 µl H2O. The
primers used were specific for the downstream genes of pepA1 (OL3094, OL3095),
pepP2 (OL3092, OL3093), pepT2 (OL3090, OL3091), and pepV (OL3088, OL3089),
while endogenous control primers were used for 16s rRNA gene.

β-galactosidase Activity Assays
The pepT-lacZ reporter gene fusions were separately plated on TSA containing 25 µl of
5 µg ml-1 erythromycin, and 25 µl of 40 µg ml-1 X-GAL. Plates were incubated at 37oC
overnight, and screened for blue colonies. Three independent colonies were then
selected from each plate, inoculated into TSB, and grown at 37oC. To deduce levels of
expression, samples in 100 µl volumes were taken, in duplicate, every hour for 8h, and
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again at 24h, placed into a fresh 1.5mL eppendorf tube, and stored at -80oC until
analysis. Once analysis could be conducted, the samples were removed from the
freezer and allowed to thaw on ice. Samples were resuspended in 0.5mL of ABT buffer,
then 100 µl of 4-MUG (4 mg/mL in DMSO) was added, and samples were incubated at
25oC for 60 minutes in the dark. Immediately after incubation, 0.5mL of 0.4 M NA2CO3
was added to stop the reaction, and the samples then mixed by inversion. Fluorescence
was measured using a BioTek Synergy 2 plate reader. The β-galactosidase activity was
determined using the following equation. (((Fluorescence –Background fluorescence) –
C) / M) x ((A / B) / (T x OD600 x V)) = β-galactosidase units mL-1 OD600-1 min-1 (C = Value
of intercept of calibration curve (Determined from fluorescence readings of known
concentrations of 4MU), M = Gradient of the calibration curve (Determined from
fluorescence readings of known concentrations of 4MU), A = Volume of the assay (1.1
mL total of 500 µl ABT, 500 µl 0.4 M Na2CO3 and 100 µl of 4-MUG), B = Volume in
Microtiter well (0.225 mL), T = Reaction time (60 min), V = Volume of cells originally
sampled (0.1 mL)).

Transcriptional Disk Diffusions
To assess transcription induction, TSA agar plates were overlaid with 5 mL of 0.07% top
agar containing 3 µg/ml-1 of X-GAL, and either the pepT1-lacZ or pepT2-lacZ fusion
strains at a 1:1000 dilution. Chemical stressors (Table 3) were subsequently applied as
previously described for stress analysis, in 10µl volumes to 7mm round sterile Whatman
Paper filter disks, which were placed, in triplicate, on the top agar. Plates were
incubated for 24 h at 37oC and screened for the presence of blue halos, which is a
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result of the cleavage of X-GAL by β-galactosidase (152), indicating induced
expression. To assess transcriptional repression, the chemical stressor disk diffusion
assays were performed as described above, with top agar containing 4 µg/ml-1 of X-GAL
and either the pepT1-lacZ or pepT2-lacZ fusion strains at a 1:1000 dilution. Plate were
incubated for 24 h at 37oC and screened for the presence of yellow halos, indicating the
repression of transcription due to no X-GAL being cleaved by β-galactosidase.

Proteomic Assays.

Protein Extraction
Secreted, cytoplasmic, and intracellular proteins were harvested from 100mL
synchronized cultures of wild-type, pepT1, and pepT2 mutant grown to the desired time
point. Following centrifugation for 10 minutes at 4150 rpm, the supernatants were then
collected in 50 µl fractions, and measured for protein concentration using a Pierce 660
nm protein assay kit (supernatant protein fraction). The remaining pellets were
resuspended in sterile PBS, and 1mL of the suspension placed into a fresh 50mL tube.
Lysostaphin (10 µl) was then added, and the samples were incubated at 37oC for 30
minutes in a waterbath. Following, 2 µl of DNAseI enzyme was added, and the samples
incubated in a waterbath for an additional 30 minutes at 37oC. The samples were then
centrifuged at 12,000 rpm for 5 minutes, and the supernatants collected and measured
for protein concentration (intracellular protein fraction). The remaining pellet was
resuspended in 100 µl UDS buffer, and measured for protein concentration (cell
wall/membrane protein fraction).
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Western Blot Analysis
Secreted, cytoplasmic, and intracellular proteins were harvested from 100mL
synchronized cultures of pMK4::wild-type, pMK4::pepT1-His6, and pMK4::pepT2-His6
tagged cells, grown to the desired time point. As a negative control, proteins were
harvested from a wild-type strain containing an empty pMK4 vector (EV). Standardized
amounts of protein were resolved on an SDS-page gel, followed by transfer to a PVDF
membrane. His6 tagged proteins were probed for using an anti-His antibody, detected
using a secondary antibody, and then visualized by X-ray exposure.

Desalt
MacroSpin columns were activated by pipetting 500 µl of acetonitrile (ACN) onto the
column, and centrifuged at 1,100 rpm for 1 minute (each centrifugation follows these
parameters). Flow-through was discarded, and the column blotted dry using a Kim wipe.
The columns were then equilibrated by adding 500 µl of 0.1% formic acid, and the flowthrough again discarded. The addition of formic acid and centrifugation was repeated,
for a total of two additions of 0.1% formic acid, and the flow-through discarded. Protein
samples were then added to the MacroSpin columns, centrifuged, and the flow-through
discarded. Columns were washed by pipetting 500 µl of 0.1% formic acid, and the flowthrough discarded. This step was repeated, for a total of two column washes. Samples
were then eluted into fresh 2mL eppendorf tubes by pipetting 250 µl of 90:10 ACN:H2O
onto the columns, and vacuum dried, and stored at 4oC until analysis.
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N-Terminomics
We first collected 4 mg/ml of cytoplasmic proteome of our wild-type, pepT1, and pepT2
mutant strains (Fig. 1A), in triplicate, as described by us previously (153). Dry
guanidinium hydrochloride was added to a 6 M final concentration to inactivate
proteases, and disulfides reduced by adding DTT to a 10mM final concentration. The
samples were then vortexed, and incubated on a 95oC heat block for 10 minutes. Once
the samples were cooled to room temperature, cysteines were alkylated by adding
iodoacetamide to a 30mM final concentration, and the samples incubated in the dark, at
room temperature, for 30 minutes. Lysine residues in the samples were then converted
to homoarginines by adding 0.5 M o-methylisourea (final concentration), and incubated
overnight at 4oC to allow for the complete modification of lysine residues without
reacting with N-termini. The following day, PD-10 columns were equilibrated with 25mL
of 8 M urea, and the protein samples were then buffer exchanged into 8 M
urea/HEPES. The desalted samples were collected, and N-terminal amines were then
tagged by adding 5 mM sulfo NHS-SS-biotin for 1 hour at 37oC (Fig. 1B). Adding 1 M
ammonium bicarbonate pH 7.8, to reach a final concentration of 50mM, terminated the
tagging reactions. The samples were subsequently treated with a 40mM final
concentration of 1 M stock hydroxylamine for 15 minutes at 37oC to remove any low
frequency side reactions that may have occurred between the biotin and
serine/threonine residues. The samples were buffer exchanged again into an 8M
urea/HEPES buffer. Protein samples were then diluted to 2 M urea with 50mM
ammonium bicarbonate, and digested with 5 µg of modified sequence grade trypsin at
37oC overnight (Fig. 1C). The following day, 500 µl of high-capacity neutravidin resin
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was added to each sample in order to bind the biotinylated N-terminal peptides.
Samples were incubated at 4oC with rocking for 30 minutes, then loaded onto 2mL
polystyrene columns, and washed extensively with 2M urea/HEPES buffer. Three
column volumes of 50mM ammonium bicarbonate were then added, and the samples
collected by pipetting out the resin left on the top of the column using 1mL of 50mM
ammonium bicarbonate, into sterile 1 ml microcentrifuge tubes. The biotin tags were
removed by adding DTT to a 50mM final concentration, and the samples were
subsequently incubated at 37oC with rocking for 30 minutes. Samples were then eluted
through Micro-Bio chromatography columns into 1 ml microcentrifuge tubes (Fig. 1D),
desalted as previously described, and vacuum dried for mass spectrometry analysis.
The N-terminomic samples were analyzed by HPLC-MS/MS using the Orbitrap XL. After
analysis, the data was searched on MASCOT against a complete S. aureus proteome.
The data files were then loaded onto Scaffold in order to evaluate peptide and protein
identifications. A normalized T-Test of the total ion current (TIC) was then performed
against the total identified protein data-set with a significance level threshold of p <=
0.05. The abundance of N-terminal peptides identified for each protein was averaged
from triplicate samples of wild-type and mutant proteomes. This average was then used
to determine significant differences in N-terminal peptide abundance from the mutant
proteomes as compared to the wild-type.
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Figure 1. N-Terminomics Workflow. Example of the N-terminomics workflow with a
wild-type, and mutant strain. The thick blue lines represent a protein substrate target of
a single aminopeptidase, while the thick orange lines represent a protein that is not a
target of an aminopeptidase. Cytoplasmic proteomes of wild-type, and mutant (pepT1,
and pepT2) were collected, in triplicate (A). As shown above, the N-terminal amine of
the wild type substrate target (thick blue line) has been cleaved and is thus shorter,
while the substrate target in the mutant has an intact N-terminus, due to the absence of
the aminopeptidase. Proteins that are not a target of the aminopeptidase, (thick orange
line) stay the same size. N-terminal amines were then tagged by adding 5 mM sulfo
NHS-SS-biotin for 1 hour at 37oC (B). Protein samples were then diluted, and digested
with 5 µg of modified sequence grade trypsin at 37oC overnight (C). High-capacity
neutravidin resin was added to bind biotinylated peptides, and the samples were
washed extensively. Biotin tags were removed by adding DTT, and the samples were
then eluted through Micro-Bio chromatography columns into 1 ml microcentrifuge tubes
(D), desalted, and vacuum dried for HPLC-MS/MS analysis.
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Results

Exploration of S. aureus Aminopeptidases. From a bioinformatics analysis previously
performed by our lab, S. aureus has thirteen putative aminopeptidase enzymes
encoded within its genome (Table 4). Of these thirteen, a mutation in one (AmpS/PepS)
was previously identified as having a growth defect in an anti-sense mutagenesis
screen

(154).

Additionally,

our

lab

has

characterized

LAP/pepZ,

a

leucine

aminopeptidase necessary for virulence in S. aureus (131). The role of an additional
aminopeptidase can be hypothesized based on homology: PepM, is a methionine
aminopeptidase that is well studied in many organisms as an essential protein
responsible for cleaving N-terminal methionine residues from newly synthesized
proteins and peptides (123). In order to explore the role of the uncharacterized eleven
aminopeptidases (including PepS) in S. aureus, we utilized the Nebraska Transposon
Mutant Library (NTML), which consists of bursa aurealis transposon insertions within all
non-essential genes in the S. aureus genome (144).

Operon Structure Analysis and Mutagenesis of the NTML Aminopeptidase
Mutants. Mutations for the eleven uncharacterized aminopeptidases were first
transduced from the S. aureus JE2 background to the USA300 Houston wild-type strain
(our lab strain of choice). Before performing work with these mutants, the operon
structures were analyzed from existing lab RNAseq data (147), in order to determine
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Table 4. The Aminopeptidases of S. aureus
Name

Classa

Familyb

Annotationc

Polarityd

Name

Classa

Familyb

Annotationc

Polarityd

pepA1

Aminopeptidase

M42.001

SAUSA300_1691

Yes

pepA2

Aminopeptidase

M42.001

SAUSA300_2400

No

pepA3

Aminopeptidase

M42

SAUSA300_1261

No

pepF1

Oligopeptidase

M03.007

SAUSA300_0902

No

pepF2

Oligopeptidase

M03

SAUSA300_1278

No

pepT1

Tripeptidase

M20.003

SAUSA300_0727

No

pepT2

Tripeptidase

M20.018

SAUSA300_1460

No

pepM

Aminopeptidase

M24.001

SAUSA300_1869

N/A

pepP1

Aminopeptidase

M24.006

SAUSA300_1654

No

pepP2

Dipeptidase

M24.008

SAUSA300_1491

No

pepS

Aminopeptidase

M20.005

SAUSA300_1860

No

pepV

Dipeptidase

M24.004

SAUSA300_1697

Yes

pepZ

Aminopeptidase

M17

SAUSA300_0845

No

* aAminopeptidases are assigned as putatively cleaving single, di, tri, or multiple (oligo)
amino acids from protein and peptide substrates based on homology analysis.
b
Shown are families for each aminopeptidase enzyme, classified based on putative
amino acid specificity and the necessity of metal cofactors, from by the MEROPS
peptidase database
c
Gene annotation from the S. aureus USA300 genome
d
Notation as to whether the transposon insertion for relevant genes causes
transcriptional defects in genes located downstream (determined herein by qPCR)
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possible polar effects caused by the transposon insertions (Figure 2 A-K). This was
done in order to ensure any phenotypes seen were not due to transcriptional defects in
genes downstream of the transposons. From this comparison, six mutations (pepA2,
pepA3, pepF1, pepF2, pepP1, and pepT1) were determined to be nonpolar (Figure 2 AF), while five mutations (pepA1, pepP2 pepT2 pepV, and pepS) were determined
putatively polar (Figure 2 G-K). Of the non-polar insertions, pepA2, pepA3, pepF2 and
pepP1 were all deemed to be monocistronic; whilst pepF1 appears to be the second
gene in a two-gene operon; and pepT1 is the third gene in a three-gene operon. For the
putatively polar insertions, pepA1 is located upstream of several genes in a large
operon, pepP2, pepT2 and pepV are each the upstream gene of separate two gene
operons, and pepS is the second gene in a three gene operon (Fig. 2K). Interestingly,
the gene downstream of pepT2 is gnd, which encodes for 6-phosphogluconate
dehydrogenase, an essential protein in S. aureus (138, 155). As such, it appears
unlikely that the pepT2 insertion could be polar. To determine if this is in fact the case,
real time PCR analysis was performed to determine which, if any, of the putatively polar
mutations cause effects of their neighboring, downstream genes. For this analysis,
genes showing no fold change in transcript for the mutant strain versus the wild-type
were determined to be non-polar, whilst those showing significant deviation (increased
or decreased) compared to the parent were considered polar. The gene downstream of
pepA1 (SAUSA300_1690) was identified as having a 1.6-fold decrease in transcript for
the mutant strain versus the wild-type (Fig. 3A). Although the fold change pepA1 is not
considered significant by student’s t-test, the potential for problems was deemed too
large to risk, and the insertion was thus determined to be polar. The gene downstream
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Figure 2. RNA Sequence Analysis of Aminopeptidase Operon Structure in S.
aureus. Shown are the eleven aminopeptidase genes taken from CLC Genomics
Workbench analysis of S. aureus USA300 Hou RNAseq using exponentially growing
cultures (139). Genes are represented as arrows according to the direction of their
transcript, and gene names are indicated in bold. The red and green lines represent
RNA sequence reads. Green reads map to the positive sense strand, while red reads
map to the antisense strand. Genes putatively located in an operon are grouped by a
thick black line.
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of pepP2 (SAUSA300_1490) was identified as having a negligible 0.8-fold increase in
transcript in the mutant strain, indicating this is a nonpolar insertion (Fig. 3B). Similarly,
the gene downstream of pepT2 (SAUSA300_1459) also had a marginal 0.8-fold
increase in transcript for the mutant, and was determined to be nonpolar (Fig. 3C).
Finally, the gene downstream of pepV (SAUSA300_1696) was identified as having a 8fold decrease in transcript for the mutant strain, making this mutation strongly polar (Fig.
3D). Prior to the completion of this work, a silent, non-polar mutant for pepS was
constructed by others in the lab; thus abrogating the need to assess this mutant.

Growth Analysis of the Remaining Non-Essential S. aureus Aminopeptidase
Mutants. Typically, aminopeptidases are believed to play a role in nutrition and
metabolism, by liberating amino acids from peptides imported into the cell (119).
Interestingly, the previously characterized LAP/pepZ mutant was not found to have any
defects in growth for any media tested (130). To explore the impact of disrupting the
remaining, non-essential aminopeptidases, we first determined the ability of the S.
aureus aminopeptidase mutants to grow in TSB, a nutrient rich media. Exponentially
growing USA300 Houston wild-type strain, as well as each of the eleven
aminopeptidase mutant strains were separately inoculated into TSB, in triplicate, at a
starting optical density (OD600) of 0.05, and allowed to grow for 6h at 37°C with shaking.
In order to determine cell growth, samples were taken every hour and their ODs were
measured. We found that none of the aminopeptidase mutant strains showed
differences in growth as compared to the wild-type strain (Fig. 4), including for
ampS/pepS, a mutation in which was previously identified in an anti-sense mutagenesis
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Figure 3. Quantitative Real-Time PCR Analysis to Determine Polarity of NTML
Insertions. Quantitative real time PCR analysis was performed for the genes
immediately downstream of aminopeptidase transposon insertions to assess polarity.
Shown is data from the USA300 Houston wild-type compared to the denoted mutant
strain. The 16S rRNA gene was used as an internal control, as described in the
methods. The downstream genes were pepA1 (SAUSA300_1690), pepP2
(SAUSA300_1490), pepT2 (gnd), and pepV (SAUSA300_1696). All experiments were
performed in triplicate. Significance was determined using a student’s t-test (****, p <
0.0001), error bars shown ±SEM.
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screen (154), as resulting in a growth defect. As such, in our study, it appears that all
eleven aminopeptidase enzymes are dispensable for growth in TSB.

In several Lactobacillus species, aminopeptidase enzymes are necessary to allow the
organism to exploit protein-rich environments in order to survive (156). Exogenous
proteins are first broken down by extracellular proteases, and the resulting peptides are
imported into the cell and N-terminally cleaved by aminopeptidases; this process
releases free amino acid constituents which can then be utilized in metabolic pathways
(119). In order to determine if the PepT1 and PepT2 enzymes are necessary for the
degradation of peptides for metabolism, we assayed their ability to grow in a peptiderich environment. Exponentially growing wild-type cells, as well as those for each of the
eleven aminopeptidase mutant strains, were separately inoculated, in triplicate, into
10% skim milk at a starting OD600 of 0.05, and allowed to grow for 24h at 37°C with
shaking. Samples were taken every hour, and serially diluted, before plating, in
duplicate, onto tryptic soy agar (TSA) to assess cell viability by CFU/mL. Surprisingly,
there were no differences in growth between the aminopeptidase mutant strains and the
wild-type (Fig. 5). These results demonstrate that the eleven S. aureus aminopeptidase
enzymes are not essential in the utilization of peptides during growth, suggesting that
they may have a role beyond nutrition in S. aureus, similar to that which we have
previously hypothesized for PepZ (130).
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Figure 4. S. aureus Aminopeptidases Are Not Required for Growth in TSB.
Exponentially growing wild-type, and aminopeptidase mutant strains were separately
inoculated, in triplicate, into TSB at a starting OD of 0.05. Samples were taken every
hour for 6 h, and measured for OD600. Error bars are shown ±SEM.
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Figure 5. S. aureus Aminopeptidases Are Not Necessary for Growth in Peptide
Rich Media. Exponentially growing wild-type, and aminopeptidase mutant strains were
separately inoculated, in triplicate, into 10% skim milk at a starting OD of 0.05, and
grown for 24 h at 37°C with shaking. Samples were taken every hour, and cell viability
assessed by calculating CFU/mL. Error bars are shown ±SEM.
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The Influence of S. aureus Aminopeptidases on Virulence. Previously, our lab has
characterized LAP/pepZ, a leucine aminopeptidase that is necessary for virulence in S.
aureus (131). Given the lack of function in nutrition, we explored whether the other
eleven uncharacterized aminopeptidases in S. aureus potentially have a role in
pathogenesis. To investigate this, we assessed the ability of the aminopeptidase
mutants to survive and propagate in whole human blood. Exponentially growing wildtype and aminopeptidase mutant cells were separately inoculated into whole human
blood, and incubated for 4h at 37°C with shaking. Samples were withdrawn after 4h,
and plated on TSA to determine percent recovery compared to the inocula. Of note,
nine of the aminopeptidase mutants showed no significant difference compared to wildtype strain in these tests (Fig. 6A-D). Interestingly, however, pepF2 demonstrated a 1.7fold decrease in survival compared to the inoculum (Fig. 6B). More striking was the
observation that both M20 family enzymes (pepT1 and pepT2) displayed significant
defects in survival after 4h in human blood, as compared to the wild-type strain (Fig.
6C). Specifically, we noted a 2-fold decrease for the pepT1 mutant, and even more
pronounced 3.1-fold decrease for the pepT2 mutant.

The S. aureus pepT1 and pepT2 Enzymes Are Required for Disease Causation
During Systemic Infection. Given the importance of both pepT1 and pepT2 to survival
in human blood, we next set out to assess their role in disease using a systemic model
of murine co-infection. As such, 10 mice were co-infected intravenously with a total of 5
x 10! CFU/mL of the wild-type and either the pepT1 or pepT2 mutant strains in a 1:1
ratio. The infection was allowed to progress for 7 days before the mice were
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Figure 6. Survival of S. aureus Aminopeptidase Mutants in Whole Human Blood.
Exponentially growing wild-type and aminopeptidase mutant strains were separately
inoculated, in triplicate, into whole human blood. Samples were taken after 4 h, and the
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subsequently euthanized. The kidneys, brain, heart, liver, lungs, and spleen were
harvested, homogenized, serially diluted, and plated in duplicate on TSA and TSA
containing erythromycin. The pepT1 and pepT2 mutant strains were differentiated from
wild-type by selecting for the erythromycin resistance cassette in the transposon
insertions. The bacterial burden in each organ was then quantified by calculating
CFU/mL for the WT and mutant strains. One mouse co-infected with wild-type and
pepT1 mutant strains died during the 7 day infection period and was omitted from the
study, however all mice in the pepT2 mutant co-infection survived.

Interestingly, both pepT1 and pepT2 mutants displayed a strikingly decreased ability to
cause septic infection. For the pepT1 mutant, we noted significantly diminished mutant
cell accumulation in all organs apart from the liver. The most notable of these was in the
brain, where we observed only 4.8% of the total bacterial population resulting from the
pepT1 mutant strain and 95.2% resulting from the wild-type, leading to an approximately
20.8-fold decrease in mutant cells from the inoculum (Fig. 7A). In the lungs, we
observed 14.2% of the total bacterial population resulting from the mutant strain and
85.8% resulting from the parental strain, which correlates to an approximate 7-fold
decrease in mutant cells from the inoculum (Fig. 7B). In the heart, 17.3% of the cells
recovered were from the pepT1 mutant bacteria while 82.7% were from the wild-type,
resulting in a 5.7-fold decrease in accumulation of mutant cells as compared to the total
bacterial population (Fig. 7C). In the kidneys, pepT1 mutant cells accounted for only
20.7% of the total bacteria recovered while 79.3% of cells were wild-type, leading to a
4.8-fold decrease in mutant cells from the inoculum (Fig. 7D). In the spleen, we
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observed only 23.2% of the total bacterial population resulting from the mutant strain
while 76.8% of cells were from the parental strain, leading to a 4.3-fold decrease in
accumulation of mutant cells from the inoculum (Fig. 7E). In the liver, we observed
34.3% of the total bacterial population resulting from the mutant strain and 65.7%
resulting from the wild-type strain (Fig. 7F). Although this is not significant by student’s ttest, a notable 2.9-fold decrease was observed in mutant cell accumulation from the
inoculum.

For the pepT2 mutant, we noted significantly diminished mutant cell accumulation in all
organs. The most prominent of which was the brain, where only 11.7% of the total
bacterial population resulted from the mutant strain and 88.3% from the parental strain,
correlating to a 8.5-fold decrease in accumulation of mutant cells from the inoculum
(Fig. 8A). In the heart, we observed only 17.6% of the total bacterial burden consisting
of mutant cells while 82.4% consisted of wild-type cells, leading to a 5.6-fold change
decrease of pepT2 mutant cells from the total bacterial population (Fig. 8B). In the
kidneys, we observed 21% of the bacterial population resulting from the mutant strain
and 79% from the wild-type, correlating to a 4.7-fold decrease in accumulation of mutant
cells from the total inoculum (Fig. 8C). In the lungs, pepT2 cells accounted for only
23.4% of the total bacteria recovered while 76.6% were wild-type, leading to a 4.2-fold
decrease in mutant cells from the total bacterial burden (Fig. 8D). In the spleen, we
observed only 29% of the total bacterial populating resulting from the mutant strain
while 71% were of the wild-type strain, correlating to a 3.4-fold decrease in
accumulation of mutant cells from the inoculum (Fig. 8E). Finally, in the liver, we
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Figure 7. The S. aureus pepT1 Enzyme Is Required for Disease Causation in
Murine Models of Infection. Mice were co-infected with 5 x 107 CFU/mL of the wildtype and pepT1 mutant strains in a 1:1 ratio. The infection was allowed to progress for 7
days and the mice were subsequently euthanized. The bacterial percent recovery was
quantified from the brain (A), lungs (B), heart (C), kidneys (D), spleen (E), and liver (F).
The data is represented as box-and-whisker plots. Percent recovery was determined
using median values represented as a black line in the center of the box. Significance
was determined using a student’s t-test ( **, p < 0.005; ***, p < 0.0003; ****, p < 0.0001).
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observed only 32.6% of the total bacterial load consisting of mutant cells while 67.4%
were of the parental strain, leading to an approximate 3-fold decrease in bacterial load
of the mutant from the total inoculum (Fig. 8F). These results establish the
indispensability of both the PepT1 and PepT2 enzyme in full S. aureus virulence.

Given the importance of both the pepT1 and pepT2 enzymes for disease causation in a
systemic model of co-infection, we next set out to assess the ability of a pepT1/T2
mutant to cause infection. As such, a pepT1/pepT2 double mutant was constructed, and
10 mice were co-infected intravenously as described for the single mutants above.
Interestingly, after 7 days, the pepT1/T2 mutant displayed an extraordinarily reduced
ability to cause septic infection. We observed significantly diminished mutant cell
accumulation in all organs, most notably in the heart, where we observed less than 1%
of the total bacterial burden consisting of mutant cells, and 99.37% consisting of wildtype cells, resulting in a 158.7-fold decrease in the amount of mutant bacteria recovered
compared to the total inoculum (Fig. 9A). In the brain, we observed 4.1% of the total
bacterial population resulting from the mutant strain and 95.9% resulting from the
parental strain, correlating to a 24.3-fold decrease in accumulation of mutant cells from
the inoculum (Fig. 9B). In the spleen, only 5.5% of the total cells recovered were from
the pepT1/T2 mutant bacteria, while 94.5% were wild-type, resulting in a 18-fold
decrease in accumulation of mutant cells from the total bacterial population (Fig. 9C). In
the lungs, we observed only 5.5% of the total bacterial population resulting from the
mutant strain, while 94.5% resulted of the parental strain, correlating to a 18-fold
decrease in accumulation of mutant cells from the inoculum (Fig. 9D). In the liver,
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Figure 8. The S. aureus pepT2 Enzyme Is Required for Disease Causation in
Murine Models of Infection. Mice were co-infected with 5 x 107 CFU/mL of the wildtype and pepT2 mutant strains in a 1:1 ratio. The infection was allowed to progress for 7
days and the mice were subsequently euthanized. The bacterial percent recovery was
quantified from the brain (A), heart (B), kidneys (C), lungs (D), spleen (E), and liver (F).
The data is represented as box-and-whisker plots. Percent recovery was determined
using median values represented as a black line in the center of the box. Significance
was determined using a student’s t-test ( ***, p < 0.007; ****, p < 0.0001).
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pepT1/T2 mutant cells accounted for only 6.8% of the total bacteria recovered, while
93.2% were of the wild-type strain, resulting in a 14.7-fold decrease in mutant bacterial
load compared to the total inoculum (Fig. 9E). In the kidneys, we observed only 11.3%
of the total bacterial population resulting from the mutant strain, while 88.7% were from
the wild-type strain, resulting in a 8.8-fold decrease of mutant cells from the inoculum
(Fig. 9F).

To assess our results overall, we compared the percent recovery of the pepT1, pepT2,
and pepT1/T2 mutants as compared to the wild-type from our murine models of coinfection (Fig. 10). Interestingly, in the brain, the percent recovery of the pepT1 and
pepT1/T2 double mutant bacteria is nearly the same, while the percent recovery from
the pepT2 mutant is much higher. These results suggest the absence of the PepT1
enzyme is likely the predominant factor driving the diminished mutant accumulation
phenotype seen in the brain. In the heart, liver, lungs, and spleen, the pepT double
mutant has a much lower percent recovery than the pepT1 and pepT2 single mutants
combined. These results indicate that during the single mutant models of co-infection,
the phenotype ensuing from the loss of the PepT1 or PepT2 enzyme in these organs is
being partly masked by the presence of the other enzyme. In the kidneys, the percent
recovery of the pepT1/pepT2 double mutant is approximately half of the percent
recovery seen from either the pepT single mutants, suggesting both enzymes are
equally necessary to mount a successful infection.
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Figure 9. Both S. aureus pepT Enzymes Are Required to Cause Disease in Murine
Models of Infection. Mice were co-infected with 5 x 107 CFU/mL of the wild-type and
pepT1/T2 double mutant strains in a 1:1 ratio. The infection was allowed to progress for
7 days and the mice were subsequently euthanized. The bacterial percent recovery was
quantified from the heart (A), brain (B), spleen (C), lungs (D), liver (E), and kidneys (F).
The data is represented as box-and-whisker plots. Percent recovery was determined
using median values represented as a black line in the center of the box. Significance
was determined using a student’s t-test ( ****, p < 0.0001).
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Mutants in Murine Models of Infection. Percent recovery comparison of the pepT1,
pepT2, and pepT1/T2 double mutant relative to the wild-type in murine models of coinfection.
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Investigating the Role of PepT1 and PepT2 in ex vivo Models of Human Infection.
In order to assess how the pepT1/pepT2 double mutant survives and propagates in
whole human blood compared to the other aminopeptidase mutants, exponentially
growing wild-type, pepT1, pepT2, pepT1/T2 mutant, as well as their respective pepT1
and pepT2 complement strains, were separately inoculated into whole human blood,
and incubated for 4h at 37°C with shaking. Samples were withdrawn after 4h, and
plated on TSA to determine percent recovery compared to the inocula. As observed
before, both M20 family single enzyme (pepT1 and pepT2) mutants demonstrated
significantly decreased ability to survive and propagate in whole human blood after 4h,
as compared to the wild-type strain (Fig. 11). Specifically, we noted a 4.1-fold decrease
for the pepT1 mutant, and a 2.5-fold decrease for the pepT2 mutant. In addition, the
pepT1 and pepT2 complement strains show no difference in survival compared to the
parental strain, suggesting the respective phenotypes are a result of the absence of the
pepT1 and pepT2 enzymes. Of interest, we observed a striking 14-fold decrease in
percent survival for the pepT1/pepT2 mutant compared to the parental strain. Because
the fold change in percent survival for the pepT double mutant is much lower than the
pepT single mutants combined, these results suggest that the phenotypic effects from
the loss of either PepT1 or PepT2 is strongly additive, and that in the single mutants this
is being counteracted by the presence of the other enzyme, similar to that which we
observed in the heart, liver, lungs, and spleen during systemic models of co-infection.

To explore the blood survival defect further, we next sought to investigate the role of
these enzymes during interaction with host immune cells. As such, immortalized THP-1
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Figure 11. Survival Analysis of pepT Mutant Strains in Whole Human Blood.
Exponentially growing wild-type, pepT1, pepT2, pepT1/pepT2 double mutant, as well as
pepT1 and pepT2 complement strains were separately inoculated, in triplicate, into
whole human blood. Samples were taken after 4 h, and the percent survival calculated
by CFU/mL compared to the inoculum. Significance was determined using a student’s ttest ( * ,p < 0.05; **, p < 0.005), error bars are shown ±SEM.
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human macrophage-like cells were separately infected with 106 CFU/mL of the wildtype, pepT1, pepT2, and pepT1/T2 mutant bacteria. Phagocytosis was allowed to
progress for 1h at 37°C with 5% CO2, and then gentamicin was added to kill any
extracellular bacteria. The macrophages were subsequently lysed, and intracellular
bacterial loads were serially diluted and plated on TSA to determine percent
phagocytized compared to inocula. Upon analysis, we determined that 26.7% of the
wild-type bacteria infected were phagocytized (Fig. 12A). In contrast, both the pepT1
and pepT2 mutants showed decreased ability to evade phagocytosis. Specifically,
nearly 50% of the total pepT1 mutant bacteria infected were phagocytized,
corresponding to a 1.8-fold increase in mutant cells as compared to wild-type. In
addition, 60% of the total pepT2 bacteria were phagocytized, corresponding to a 2.2fold increase in mutant cells as compared to wild-type. Interestingly, the pepT1/T2
mutant displayed enhanced phagocytosis at levels comparable to the single mutants
(60% cells phagocytized, 2.2-fold increase). These results indicate that both the PepT1
and PepT2 enzymes are needed together in order to successfully evade phagocytosis,
and that loss of both is not additive to the phenotype.

To assess the ability of the mutants to survive inside host immune cells, the
phagocytosis assay was performed again in an identical manner; however, we allowed
them to proceed for 24h. When the percent survival of the wild-type was studied, we
determined that 4.3% of the total bacteria phagocytized survived (Fig. 12B). Importantly,
after this time only 2.4% of the total pepT1 mutant bacteria phagocytized were found to
have survived, correlating to a 1.8-fold decrease as compared to the wild-type. For the
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pepT2 mutant we noted 1.5% of the total cells phagocytized were recovered, which
correlates to a 3-fold decrease as compared to wild-type. Of special interest, 1.3% of
the pepT1/T2 mutant bacteria were able to survive after 24h, displaying a 3.3-fold
decrease as compared to wild-type. Once again, the pepT double mutant showed
decreased survival at levels comparable to the single mutants. Thus it would appear
that the presence of both the PepT1 and PepT2 enzymes together is necessary for
survival inside host immune cells, and suggests that in this environment, the function of
one enzyme is masked by the other.

The Defect in pepT1 and pepT2 Mutant Strain Pathogenesis is Not Mediated by
Impaired Synthesis of Virulence Factors. In order to determine if the virulence
phenotypes seen for the pepT mutants are facilitated by altered production of virulence
factors, wild-type, pepT1, pepT2, and pepT1/T2 double mutant strains were inoculated
onto TSA, blood agar (hemolytic activity), casein agar (protease activity), as well as
nuclease agar (nuclease activity), to examine deficits in virulence factor production. An
agr mutant strain was included as a control, due to its lack of hemolytic and proteolytic
activity. No differences in growth on TSA (a nutrient rich agar) were seen for any of the
mutant strains as compared to wild-type (Fig. 13A). There were also no differences in
hemolytic activity, protease activity, or nuclease activity seen for the mutant strains as
well (Fig. 13B-D), suggesting these enzymes do not influence the activity of key
virulence factors.
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Figure 12. The pepT Mutants Have a Decreased Ability to Evade and Survive
Inside Human Immune Cells. THP-1 human macrophage-like cells were separately
infected with wild-type, pepT1, pepT2, and pepT1/T2 double mutant strains, in triplicate.
(A): Phagocytosis was allowed to proceed for 1 h, and the percent cells phagocytized
calculated by CFU/mL compared to inoculum. (B) Phagocytosis assay was allowed to
proceed for 24 h, and the intracellular percent survival was calculated by CFU/mL
compared to CFU/mL phagocytized. Significance was determined using a student’s ttest ( * ,p < 0.05; **, p < 0.005), error bars are shown ±SEM.
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Figure 13. The Avirulent Phenotype of the pepT Single and Double Mutants Is Not
Associated with Altered Production of Virulence Factors. Wild-type, pepT1, pepT2,
pepT1/T2 and agr mutant strains were inoculated onto TSA (A), sheep blood agar (B),
casein nutrient agar (C), and nuclease agar (D), to determine key virulence factor
activity.
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To further quantify potential hemolytic activity, culture supernatants from the wild-type,
pepT1, pepT2 and pepT1/pepT2 mutant strains were separately inoculated, in triplicate,
into whole human blood and incubated at 37oC for 40 minutes. The OD543 of resulting
supernatants was then assessed as a measure of hemolytic activity; with untreated
samples used as a control. As expected, none of the mutant strains displayed any
differences in hemolysis as compared to the parental strain (Fig. 14). These results
strongly indicate the decreased infection observed for mutant strains is not the result of
altered production of virulence factors.

Assessing the Role of PepT1 and PepT2 in Biofilm Formation. Many of the
diseases caused by S. aureus are associated with the formation of a biofilm within the
host (157-159). Essentially, a biofilm is a microbial community embedded in a selfproduced extracellular matrix that is semi-permanently attached to host tissues (160).
As previously described, proteases have been shown to play several roles in the
modulation of S. aureus biofilm formation and dispersal. As such, we wanted to explore
the impact of PepT1, and PepT2 on biofilm formation using ex-vivo models of biofilm
attachment. Overnight cultures of wild-type, SH1000, 8325-4, pepT1, pepT1
complement, pepT2, pepT2 complement, pepT1/T2, were separately grown, in
triplicate. The S. aureus SH1000 strain was used as a positive control, and the S.
aureus 8325-4 strain was used as a negative control. Cultures were then added to a 96well microtiter plate containing 20% human plasma, and incubated at 37oC for 24 hours.
Biofilms were then fixed with 100% ethanol, and stained with crystal violet. Biofilm
growth was quantified by measuring absorbance levels of the eluted crystal violet. Of
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Figure 14. The PepT1 and PepT2 Enzymes Do Not Influence Hemolysis Activity.
Culture supernatants from the wild-type, pepT1, pepT2, and pepT1/T2 mutant strains
were separately inoculated, in triplicate, into whole human blood and incubated at 37oC
for 40 minutes. Hemolytic activity was assessed by measuring the OD543 of resulting
supernatants. Untreated samples were used as a control. Hemolysin units were
determined using the formula (OD543 x 100) / (mL supernatant) x (min) x OD600. Error
bars are shown ±SEM.
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note, none of the mutants tested displayed any significant decreases in biofilm
formation as compared to wild-type strain (Fig 15). These results suggest that the
PepT1 and PepT2 enzymes minimally contribute to S. aureus biofilm formation.

Cellular Localization of PepT1 and PepT2. Despite no evidence of a signal sequence
in either of the PepT enzymes, we next explored their cellular localization. This is of
importance, because if these enzymes were secreted, it would readily explain their
apparent role in virulence. As such, we utilized pMK4 plasmid shuttle vectors, which
were separately constructed and contained the pepT1 and pepT2 genes bearing a Cterminal 6-histidine tag. Cytoplasmic, membrane, and secreted protein fractions were
obtained from USA300 wild-types harboring these plasmids after 15h growth, and
subjected to Western blot, using an anti-His6 antibody. Upon analysis, both the PepT1
and PepT2 enzymes were concluded to be located intracellularly (Fig. 16) with no
evidence of either seen in the membrane or secreted protein fractions. To determine the
cellular amounts of PepT1 and PepT2, we performed Western blot analysis as
previously described at various intervals during growth, including 3h, 6h, 9h, and 24h.
Both the PepT1 and PepT2 enzymes were seemingly produced at equivalent levels
during each time point (Fig. 17).

Growth Analysis of the pepT1/pepT2 Double Mutant. Although neither the pepT1 or
pepT2 single mutants displayed any growth defects in TSB, we next set out to explore
whether the absence of both enzymes would have any effects on growth. Importantly,
the pepT1/pepT2 mutant strain displayed no differences in growth as compared to the

78

2.5

2.0

OD595

1.5

*
1.0

0.5

0.0

WT

SH1000

8325-4

pepT1

pepT1 Comp

pepT2

pepT2 Comp

pepT1/T2

Figure 15. The S. aureus pepT Enzyme Mutants Are Not Required for ex vivo
Biofilm Formation. Overnight cultures of wild-type, SH1000, 8325-4, pepT1, pepT1
complement, pepT1, pepT2 complement, and pepT1/T2 mutant strains were separately
grown, in triplicate, in biofilm media, and then incubated with 20% human plasma at
37oC for 24 h in a 96-well microtiter plate. Biofilms were fixed with 100% ethanol
followed by staining with crystal violet. Biofilm growth was calculated by measuring the
OD595 of the crystal violet elution. Significance was determined using a student’s t-test (
* ,p < 0.05), error bars are shown ±SEM.
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Figure 16. PepT1 and PepT2 Are Intracellular Enzymes. pMK4 plasmid vectors
encoding histidine tagged forms of the PepT1 and PepT2 enzymes were transduced
into the respective USA300 Houston background. The cytoplasmic, membrane, and
secreted protein fractions were obtained after 15h growth, and are shown. An empty
pMK4 vector was used as a control (EV). Molecular weight markers are indicated, in
kDa.
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Figure 17. PepT1 and PepT2 Are Produced Constitutively during Growth.
Cytoplasmic protein fractions are shown at time points 3 h (lanes 1, 5, and 9), 6 h (lanes
2, 6, and 10), 9 h (lanes 3, 7, and 11), and 24 h (lanes 4, 8, and 12). An empty vector
was used as a control (EV). Molecular weight markers are indicated, in kDa.
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wild-type strain (Fig. 18). Next, to assess the ability of the pepT1/pepT2 mutant to
proliferate in a peptide rich environment, the pepT1/T2 mutant strain was inoculated into
10% skim milk and allowed to grow for 24h. Again we observed no differences in growth
between the double mutant strain as compared to the wild-type (Fig. 19).

Analysis of the pepT1 and pepT2 Mutants in Response to Oxidative Stress. During
an ex vivo model of human infection, we determined our pepT1 and pepT2 gene
mutants to have increased sensitivity towards phagocytosis and killing by THP-1
macrophages. Importantly, oxidative stress via reactive oxygen species (ROS) is a
critical method by which phagocytes damage and kill bacteria (161). Therefore, we
wanted to examine the ability of the pepT1 and pepT2 mutant strains to survive
exposure to oxidative stress. As such, exponentially growing wild-type, pepT1, and
pepT2 mutant strains were subjected to the addition of 150mM H2O2. No differences in
percent survival were seen for either the pepT1 or pepT2 mutants as compared to the
wild-type strain, after H2O2 exposure (Fig. 20), suggesting these enzymes are not
essential in response to oxidative stressors.

Phenotypic Analysis of the pepT Single and Double Mutants to Explore Further
the Avirulent Phenotype. We next sought to derive explanation for the avirulence
phenotype of the pepT mutant strains using a battery of phenotype analyses. Firstly, we
grew the mutant strains in amino acid limiting media. Cultures were allowed to grow for
7 days at 37oC static, as well as with shaking. We found neither the pepT1 nor pepT2
mutant to have differences in growth compared to the wild-type (Fig. A-1). Next
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Figure 18. The pepT1/T2 Double Mutant Does Not Display A Growth Defect in
TSB. Exponentially growing wild-type, and pepT1/T2 double mutant strains were
separately inoculated, in triplicate, into TSB at a starting OD of 0.05. Samples were
taken hourly for 6 h, and measured for OD600. Error bars are shown ±SEM.
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Figure 19. The M20 Family Enzymes, PepT1 and PepT2, Are Not Necessary for
Growth in Peptide Rich Media. Exponentially growing wild-type, and pepT1/pepT2
double mutant strains were separately inoculated, in triplicate, into 10% skim milk at a
starting OD of 0.05, and grown for 24 h at 37°C with shaking. Samples were taken
every hour, and cell viability assessed by calculating CFU/mL. Error bars are shown
±SEM.
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Figure 20. The pepT1 and pepT2 Mutants Are Not Involved in Oxidative Stress
Response. Exponentially growing wild-type, pepT1, and pepT2 mutants were exposed,
in triplicate, to 150mM H2O2 for 10 minutes at room temperature. Samples were taken at
0, 5, and 10 minutes, serially diluted, and plated in duplicate on TSA. Percent survival
was determined by calculating CFU/mL compared to the inoculum. Error bars are
shown ±SEM.
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we used toluene and oleic acid to assess membrane integrity. We again found no
differences in membrane integrity for the pepT1 or pepT2 mutant as compared to the
parental strain, when subjected to either toluene (Fig. A-2A), or oleic acid (Fig. A-2B). In
order to better understand the role of the PepT1 and PepT2 enzymes in membrane
disruption and autolysis, we sought to assess the response of our wild-type, and
pepT1/T2 strains to a the detergent, Triton X-100. As such, a Triton X-100 induced
autolysis assay was performed. Again, we observed no notable defects in survivability
for any strain (Fig. A-3).

It has been previously shown that expression of a PepT homologue in Salmonella
typhimurium is induced by anaerobiosis (162, 163). In order to explore the role of the
PepT1 and PepT2 enzymes in anaerobic growth, exponentially growing wild-type,
pepT1, pepT2, and pepT1/T2 mutant strains were separately inoculated, in triplicate, in
TSB, and allowed to grow for 24h anaerobically. Cultures were then grown in two
conditions: 37oC with shaking, or well as 37oC statically. We found neither the pepT1,
pepT2, nor pepT1/T2 mutants to have differences in percent survival when grown
anaerobically, both at 37oC with shaking (Fig. A-4A), and at 37oC statically (Fig. A-4B).
These results suggest the PepT1 and PepT2 enzymes are not necessary to growth
under anaerobic conditions. The response of the pepT1 and pepT2 mutants to
anaerobic conditions was also assessed using specialty media. The experiment was
performed using TSA, sheep blood agar, casein nutrient agar, nuclease agar, amino
acid limiting media, as well as mannitol salt agar (MSA). Plates were separately
inoculated using three isolated bacterial colonies from the respective wild-type, pepT1,
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pepT2, pepT1/T2 mutant strains, and grown in parallel under both aerobic and
anaerobic conditions at 37oC overnight. We found no growth impairment of any strain,
as compared to wild-type for each growth media (results not shown).

In order to further investigate the response of pepT1, pepT2, and pepT1/T2 to external
stimuli, we set out to determine whether exposure to various chemical stressor
compounds would alter cellular survival as compared to the parental strain. This was
achieved by performing disk diffusion assays to expose the wild-type, pepT1, pepT2,
and pepT1/T2 mutant strains to a wealth of chemical stressor compounds (Table 3). As
such, TSA agar plates were overlaid with 5 mL of 0.07% top agar containing the wildtype, pepT1, pepT2, or pepT1/T2 mutant strains at a 1:1000 dilution. Chemical
stressors were subsequently applied in 10µl volumes to 7mm round sterile Whatman
Paper filter disks, which were placed, in triplicate, on the top agar. Plates were
incubated for 24h at 37oC and screened for differences in susceptibility as compared to
the parental strain. Upon observation, we determined there to be no significant
differences in susceptibility of the pepT1, pepT2, or pepT1/T2 mutants as compared to
wild-type (data not shown).

Transcriptional Profiling of the pepT1 and pepT2 Mutants During Growth. Previous
Western blot data has demonstrated that the PepT1 and PepT2 enzymes appear to be
constitutively produced by S. aureus cells. In order to understand how their production
is mediated at the level of transcription, we created pepT1 and pepT2 lacZ reporter
gene fusion strains. Strains were grown in TSB at 37oC with shaking, and samples were
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taken every hour for 8h, and again at 24h. Samples were then measured for βgalactosidase activity using 4-MUG as a substrate. Results for both strains show pepT1
and pepT2 to have near identical expression patterns, with maximal transcription in TSB
occurring 1h post-inoculation, followed by a steady decrease in expression throughout
the remaining hours (Fig. 21). These results were slightly different than our previous
Western blot data, which demonstrated that both the PepT1 and PepT2 enzymes were
seemingly produced at equivalent levels during each time point of 3h, 6h, 9h, and 24h.

We next sought to assess the effects of external stimuli on pepT1 and pepT2
expression by exposure to our panel of chemical stressors (Table 3). TSA agar plates
were overlaid with agar containing 3 µg/ml-1 of X-GAL, and either the pepT1-lacZ or
pepT2-lacZ fusion strains at a 1:1000 dilution. Chemical stressors were subsequently
applied to sterile filter disks, which were placed, onto the agar. Plates were incubated
for 24h at 37oC and screened for the presence of blue halos around the perimeter of
disks, which would result from cleavage of X-GAL by β-galactosidase (152), indicating
induced expression. Interestingly, three chemicals were found to induce both pepT1 and
pepT2 expression: phosphomycin, oxacillin, and penicillin-G, all of which disrupt
bacterial cell wall synthesis (115, 164, 165). To assess transcriptional repression, the
chemical stressor disk diffusion assays were performed as described above, with top
agar containing 4 µg/ml-1 of X-GAL and either the pepT1-lacZ or pepT2-lacZ fusion
strains at a 1:1000 dilution. Plate were incubated for 24h at 37oC and screened for the
absence of blue halos, indicating the repression of transcription due to no X-GAL being
cleaved by β-galactosidase. Upon observation, we determined there to be no significant
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Figure 21. Maximal Transcription of pepT1 and pepT2 Occurs During Early
Exponential Phase. USA300 strains containing the pepT1-lacZ or pepT2-lacZ reporter
fusions, were separately grown, in triplicate, in TSB at 37oC with shaking for 24 h.
Samples were taken every hour for 8 h and again at 24 h to measure β-galactosidase
activity. Error bars are shown ±SEM.
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repression of pepT1 or pepT2 transcription when exposed to the chemical stressor
library.

N-Terminomic Analysis to Ascertain Pathophysiological Targets of the PepT1 and
PepT2 Aminopeptidases Within S. aureus Cells. Primarily, aminopeptidases are
known to be involved in the turnover of exogenously imported proteins in order to aid in
cellular nutrition (166). These important enzymes function by cleaving either single, or
multiple amino acid residues from the N-terminus of proteins and peptides, and it’s
these amino acid constituents that are then recycled for various cellular processes.
Conversely, aminopeptidases can also play a role in protein bioactivation or inactivation
cascades, by selectively cleaving residues of target proteins in order to form an active
from of a relatively inactive precursor protein, and vice versa (119). In order to fully
understand the precise mechanisms and pathways by which the PepT1 and PepT2
aminopeptidase enzymes are employed in S. aureus, we sought to identify the exact
substrate targets these proteins act upon. This was explored using N-terminomics, a
cutting edge proteomics assay. N-terminomics is a high-content screen that can
effectively identify protease substrate targets and their sites of cleavage by chemically
tagging the alpha amine groups of the substrate targets post-proteolysis, enriching for
the tagged N-termini, followed by identification and analysis of collected N-termini via
Liquid Chromatography-Coupled Tandem Mass Spectrometry, LC-MS/MS (167-169).
The LC-MS/MS data is then searched against a complete proteome in order to identify
matching proteins and therefore, protease substrate targets.
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To ascertain pathophysiological targets of the PepT1 and PepT2 enzymes within S.
aureus, we performed the N-terminomics assay as previously described (167), see
materials and methods. Our N-terminomic analysis identified 344 unique proteins
across the wild-type, pepT1, and pepT2 mutant samples (Table A-1). Of these 344
proteins identified, 214 were identified in each of the wild-type, pepT1, and pepT2
mutant samples (Fig. 22), suggesting the intracellular proteome isolation and Nterminomics methods we used were successful. In order to detect significant changes in
N-terminal peptide abundance across the samples, a normalized T-Test of the total ion
current (TIC) was performed against the total identified protein data-set with a
significance level threshold of p <= 0.05. When compared to the wild-type, the pepT1
mutant data-set identified 20 proteins showing significant changes in N-terminal peptide
abundance (Table 5). More specifically, two proteins had an increase in abundance in
the pepT1 mutant as compared to the parental strain: an uncharacterized protein with a
157.2-fold increase in the mutant, and a 50S ribosomal protein L15 with a 3.39-fold
increase in the mutant. Eleven proteins showed a significant decrease in abundance in
the mutant strain as compared to the wild-type, corresponding to fold change decreases
between 89.44 and 2.70. The remaining seven proteins showing substantial changes in
N-terminal peptide abundance were only identified in the wild-type sample, and were
thus absent from the pepT1 mutant.

For the pepT2 mutant data-set, we identified 21 proteins showing significant changes in
N-terminal peptide abundance as compared to the wild-type strain (Table 6).
Specifically, three proteins had an increase in abundance in the pepT2 mutant as

91

Figure 22. Comparison of Protein Identifications from the N-Terminomic Analysis.
Venn-Diagram comparison of the proteins identified during N-terminomic analysis of our
wild-type (WT), pepT1 (T1), and pepT2 (T2) mutant strains. The center of the diagram
and highlighted in yellow represents the 214 proteins identified from the 349 proteins in
total which are found in each of the wild-type, pepT1, and pepT2 mutant strains.
Overlapping circles represent data-sets with matching protein identifications.

92

Table 5. Wild-type and pepT1 N-Terminomics Analysis
Identified Protein

Accession #

P-Value
(p <= 0.05)

Fold
Change

Quantitation

Uncharacterized protein

Q2FHC5_STAA3

0.037

157.22

Increase in T1

50S ribosomal protein L15

RL15_STAA3

0.027

3.39

Increase in T1

50S ribosomal protein L5

RL5_STAA3

0.041

89.44

Decrease in T1

50S ribosomal protein L2

RL2_STAA3

0.0068

23.91

Decrease in T1

Bifunctional purine biosynthesis
protein PurH

PUR9_STAA3

0.0025

18.31

Decrease in T1

Phosphate acetyltransferase

Q2FJ55_STAA3

0.047

16.53

Decrease in T1

Glycine betaine/carnitine/choline
ABC transporter

Q2FE52_STAA3

0.038

7.85

Decrease in T1

Phosphoribosylformylglycinamidine
synthase

Q2FI11_STAA3

0.045

6.31

Decrease in T1

50S ribosomal protein L17

RL17_STAA3

0.016

5.95

Decrease in T1

AANH-like and USP-like superfamily;
universal stress protein

Q2FG32_STAA3

0.012

5.81

Decrease in T1

Chaperone protein DnaK

DNAK_STAA3

0.023

3.65

Decrease in T1

2-C-methyl-D-erythritol 4-phosphate
cytidylyltransferase

ISPD_STAA3

0.042

2.74

Decrease in T1

Uncharacterized protein

Q2FEN1_STAA3

0.037

2.70

Decrease in T1

ATP-dependent Clp protease ATPbinding subunit ClpC

CLPC_STAA3

0.008

N/A

Found only in WT

Pur operon repressor

Q2FJE6_STAA3

0.0049

N/A

Found only in WT

Uncharacterized protein

Q2FIV7_STAA3

0.031

N/A

Found only in WT

Dihydrofolate reductase

Q2FH12_STAA3

0.0031

N/A

Found only in WT
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Table 5. (Continued)
	
  
50S ribosomal protein L16

RL16_STAA3

0.035

N/A

Found only in WT

Addiction System antitoxin
(Txe/YoeB family)

Q2FE41_STAA3

0.00037

N/A

Found only in WT

Phosphoglycerate kinase

PGK_STAA3

0.030

N/A

Found only in WT

*Listed are the proteins identified in the wild-type/pepT1 N-terminomics analysis to have
significant changes in N-terminal peptide abundance. Strains are abbreviated as
follows: T1 – pepT1 mutant; WT – wild-type. A normalized T-Test of the TIC was
performed against the total identified protein data-set with a significance level threshold
of p <= 0.05. Quantitation profiles are indicated, representing a relative increase or
decrease in peptide abundance as compared to the wild-type strain.
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compared to the parental strain: two uncharacterized proteins with a fold change
increase of 9.24 and 2.65, respectively, and a cytidine deaminase, with a 1.8-fold
increase. Fourteen proteins showed a significant decrease in abundance in the mutant
strain as compared to the wild-type, corresponding to fold change decreases between
9.92 and 1.74. Of those fourteen proteins, one in particular, ArlR, is a response
regulator of the arlRS two-component system, and has been previously shown to affect
autolysis, capsule production, the production of numerous exoproteins, and is involved
in the regulation of several virulence genes in S. aureus (86, 170, 171). The remaining
four proteins showing substantial changes in N-terminal peptide abundance were only
identified in the wild-type sample, and were thus absent from the pepT2 mutant.
Interestingly, nearly one-third of the proteins showing significant differences in Nterminal peptide abundance from both the pepT1 vs. wild-type, and pepT2 vs. wild-type
N-terminomics analysis, were ribosomal proteins.

Remarkably, seven proteins were identified in both the pepT1 and pepT2 mutants to
have a significant change in N-terminal peptide abundance as compared to the wildtype (Table 7). Even more intriguingly, six out of those seven proteins show the same
protein quantitation when compared to the wild-type. To be more specific, two 50S
ribosomal proteins (L2 and L17), and a third uncharacterized protein were all shown to
have a decreased in N-terminal abundance in both the pepT1 and pepT2 mutants as
compared to the parental strain. Furthermore, the 50S ribosomal protein L16, a
phosphoglycerate kinase, and the Pur operon repressor proteins were only found in the
wild-type strain, and not identified in either the pepT1 or pepT2 mutants. In addition,
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ClpC, an ATP-dependent binding subunit protein of the Clp protease, was shown to
have decreased abundance in the pepT2 mutant as compared to the wild-type strain,
however was not identified in the pepT1 mutant.
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Table 6. Wild-type and pepT2 N-Terminomics Analysis
Identified Protein

Accession #

P-Value
(p <= 0.05)

Fold
Change

Quantitation

Glucosamine-6-phosphate isomerase

Q2FFP1_STAA3

0.023

9.24

Increase in T2

DUF4242 superfamily;
dipeptide/oligopeptide/nickel ABC
transporter permease

Q2FK91_STAA3

0.041

2.65

Increase in T2

Cytidine deaminase

Q2FGF5_STAA3

0.027

1.80

Increase in T2

Malonyl CoA-acyl carrier protein
transacylase

Q2FHK8_STAA3

0.0017

9.92

Decrease in T2

50S ribosomal protein L2

RL2_STAA3

0.012

9.26

Decrease in T2

ATP-dependent Clp protease ATPbinding subunit ClpC

CLPC_STAA3

0.019

8.70

Decrease in T2

DNA-directed RNA polymerase
subunit omega

RPOZ_STAA3

0.028

6.09

Decrease in T2

Inositol monophosphatase family
protein

Q2FHX3_STAA3

0.0071

4.80

Decrease in T2

50S ribosomal protein L17

RL17_STAA3

0.016

4.51

Decrease in T2

Catabolite control protein A

Q2FG02_STAA3

0.03

4.04

Decrease in T2

30S ribosomal protein S5

RS5_STAA3

0.035

3.30

Decrease in T2

AANH-like and USP-like superfamily;
universal stress protein

Q2FG32_STAA3

0.0052

3.25

Decrease in T2

Uncharacterized protein

Q2FGA2_STAA3

0.018

2.92

Decrease in T2

Response regulator ArlR

ARLR_STAA3

0.044

2.90

Decrease in T2

30S ribosomal protein S8

RS8_STAA3

0.0085

2.54

Decrease in T2

50S ribosomal protein L10

RL10_STAA3

0.027

1.98

Decrease in T2

Succinyl-CoA ligase [ADP-forming]
subunit beta

SUCC_STAA3

0.039

1.74

Decrease in T2

50S ribosomal protein L16

RL16_STAA3

0.035

N/A

Found only in WT
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Table 6. (Continued)
	
  
Heme oxygenase (staphylobilinproducing) 2

HDOX2_STAA3

0.032

N/A

Found only in WT

Pur operon repressor

Q2FJE6_STAA3

0.0049

N/A

Found only in WT

Phosphoglycerate kinase

PGK_STAA3

0.030

N/A

Found only in WT

*Listed are the proteins identified in the wild-type/pepT2 N-terminomics analysis to have
significant changes in N-terminal peptide abundance. Strains are abbreviated as
follows: T2 – pepT2 mutant; WT – wild-type. A normalized T-Test of the TIC was
performed against the total identified protein data-set with a significance level threshold
of p <= 0.05. Quantitation profiles are indicated, representing a relative increase or
decrease in peptide abundance as compared to the wild-type strain.
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Table 7. Comparison of Protein Identifications
Identified Protein

Accession #

pepT1 vs. WT
Quantitation

pepT2 vs. WT
Quantitation

50S ribosomal protein L2

RL2_STAA3

Decreased in T1 Decreased in T2

50S ribosomal protein L17

RL17_STAA3

Decreased in T1 Decreased in T2

AANH-like and USP-like
superfamily; universal stress
protein

Q2FG32_STAA3 Decreased in T1 Decreased in T2

ATP-dependent Clp protease
ATP-binding subunit ClpC

CLPC_STAA3

Only in WT

Decreased in T2

50S ribosomal protein L16

RL16_STAA3

Only in WT

Only in WT

Pur operon repressor

Q2FJE6_STAA3

Only in WT

Only in WT

Phosphoglycerate kinase

PGK_STAA3

Only in WT

Only in WT

*Listed are the proteins identified in both the wild-type vs. pepT1 N-terminomics
analysis and wild-type vs. pepT2 N-terminomics analysis to have significant changes in
N-terminal peptide abundance. Strains are abbreviated as follows: T1 – pepT1 mutant;
T2 – pepT2 mutant; WT – wild-type. A normalized T-Test of the TIC was performed
against the total identified protein data-set with a significance level threshold of p <=
0.05. Quantitation profiles are indicated for each data-set, representing a relative
increase or decrease in peptide abundance as compared to the wild-type strain.
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Discussion

Traditionally, bacterial aminopeptidases have been characterized for their integral role
in protein turnover for cellular nutrition/metabolism, as well as their involvement in
protein bioactivation/inactivation pathways; only recently has it begun to emerge that
these enzymes can also contribute to bacterial pathogenesis (120). During a previous
study in our lab, we revealed a S. aureus leucine aminopeptidase mutant, LAP/pepZ, to
be attenuated in virulence in both systemic and localized models of infection (128, 130,
132). Importantly, PepZ was the first intracellular bacterial aminopeptidase found to be
involved in pathogenesis in Gram-positive bacteria. Although the exact molecular
mechanisms by which PepZ functions is still unknown, it is thought that the enzyme is
primarily responsible for the bioactivation/inactivation of key protein targets within the
cell that are involved in the secretion of virulence factors (Carroll and Shaw,
unpublished observation). These hypotheses are based on an intracellular and
extracellular proteome analysis performed using the pepZ mutant, which revealed large
alterations in protein abundance and the secretion of virulence factors as compared to
the wild-type strain (128). Notably, a foldase, PrsA, which is known to facilitate secretion
of virulence determinants in various Gram-positive bacteria, was significantly decreased
in abundance in the mutant strain, suggesting that PrsA, as a substrate of PepZ, could
mediate the avirulent phenotype observed in the pepZ mutant.
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PepZ is part of a larger family of M17 leucine aminopeptidases, which have gained
interest in recent years due to their involvement in virulence in Gram-negative
organisms such as V. cholera, and P. aeruginosa (129, 133, 134). Interestingly, the M17
aminopeptidases from both of these organisms have DNA-binding activity independent
of their function as leucine aminopeptidases, and it is through this DNA-binding ability
and transcriptional regulation that they affect virulence, which demonstrates the
multifunctional properties of these enzymes. For example, the PepA enzyme in V.
cholera is proposed to function as a DNA-binding protein, and is involved in the
negative regulation of the ToxR regulon, which activates virulence gene expression
(133). Disruption of the pepA gene resulted in the deregulation of pH in the pathogen,
thus altering the expression of several virulence proteins, which are known to be
strongly influenced by environmental and host signals (133). Furthermore, loss of the
PhpA leucine aminopeptidase gene in P. aeruginosa resulted in an increase in algD
transcription, which is the first gene in the alginate biosynthetic operon responsible for
synthesizing a polysaccharide known as alginate (134). This increase in algD
transcription mediates the switch from a nonmucoid to a highly mucoid phenotype of P.
aeruginosa during periods of chronic cystic fibrosis infection (134). However, similar to
the S. aureus PepZ enzyme, we do not believe the S. aureus PepT enzymes function in
transcriptional regulation, due to the absence of any obvious DNA-binding domains or
residues (130).

Outside of the M17 family of leucine aminopeptidases, few additional bacterial
aminopeptidases have been found to be involved in virulence. Two aminopeptidases, a
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leucine aminopeptidase and aminopeptidase T, were found to be upregulated in the
proteomes of virulent strains of Streptococcus suis, however their exact roles in
pathogenesis are still undetermined (128, 172). Additionally, a pepN aminopeptidase
mutant in S. typhimurium resulted in an increase in bacterial CFU recovery as
compared to the wild-type from the spleen, lymph node and thymus after a 5 day
infection period in a mouse model (173). It appears that PepN is important for restricting
the number of bacterial CFU during later stages of systemic infection in order to
minimize damage to the host, allowing for a successful infection that still retains a niche
within the host (173).

Because of the importance of aminopeptidases in bacterial physiology and their recently
exposed role in pathogenesis, combined with our discovery of LAP, and its involvement
in S. aureus disease causation, we set out to explore the role of the remaining eleven,
non-essential, uncharacterized aminopeptidase enzymes in S. aureus, using mutants:
pepA1, pepA2, pepA3, pepF1, pepF2, pepP1, pepP2, pepS, pepT1, pepT2, and pepV.
During our investigations, we revealed two S. aureus aminopeptidase genes, pepT1
and pepT2, as well as a respective pepT1/T2 double mutant, which appear to be
important for virulence in both ex vivo models of human infection, and in vivo models of
co-infection in mice. Importantly, the decreased fitness of the pepT mutants in whole
human blood, coupled with the inability of these mutants to mount a systemic infection
comparable to the parental strain, and their increased susceptibility to phagocytosis by
host immune cells, suggest these results would be recapitulated during human infection,
and establishes the importance of these two enzymes in S. aureus virulence.
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Additionally, our findings mark the first aminopeptidase T enzymes to be associated
with bacterial pathogenesis. Furthermore, no other S. aureus aminopeptidase mutants
tested showed significant virulence defects as compared to the wild-type, with the
exception of pepF, which showed a minor, although notable, reduction in percent
survival in blood, suggesting the S. aureus aminopeptidase enzymes play unique roles
among the cell, and are not all required for disease causation.

Typically, aminopeptidases are known to play a role in growth and metabolism by
liberating amino acid constituents from peptides imported into the cell, which can then
be used in anabolic pathways (119). Additionally, these enzymes are necessary for the
catabolism and elimination of abnormal proteins, and signal sequences derived from
secreted proteins (119, 174, 175). Studies carried out in S. typhimurium showed
significantly decreased degradation of intracellular peptides in mutant strains lacking
four broad-specificity aminopeptidases: PepA, PepB, PepD, and PepN, suggesting the
physiological necessity of these enzymes (176, 177). Similar studies were also carried
out in E. coli, where mutant strains lacking peptidase A, B, D, N, and Q were unable to
utilize peptides as a source of amino acids as at levels comparable to the wild-type
strain, demonstrating that each of the five aminopeptidases function throughout growth
and peptide utilization (178). Additionally, it has been hypothesized that the S. aureus
PepS enzyme (AmpS) plays a crucial role in cellular growth, based on the pepS gene
being picked up in a genome wide screen for its potential importance in cell growth
under basic culture conditions (141). Further studies have also shown that the
production of pepS/ampS antisense RNA, resulted in an diminished growth phenotype
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(179). In contrast to previous studies, however, we did not detect any growth
impairment of the pepS mutant when grown in TSB, and hypothesize the S. aureus
PepS enzyme likely plays a role outside of cellular growth. Furthermore, in several
Lactococcal species, aminopeptidase enzymes are necessary to allow the organism to
exploit protein-rich environments in order to survive (156). Since these species are
typically used for their fermentation abilities in the dairy industry, they are grown in milk,
which contains very few nutrients, and thus rely upon their aminopeptidase activity to
break down exogenous casein in order to supply the cell with sources of amino acids. In
order to determine if the PepT1 and PepT2 enzymes are necessary for the degradation
of peptides for metabolism, we assayed the ability of the pepT mutants to grow in TSB,
a basic nutrient medium used to grow S. aureus, and 10% skim-milk to simulate a
protein rich environment. As such, if the S. aureus PepT aminopeptidases enzymes are
involved in cell nutrition, we would expect to see a growth defect of the aminopeptidase
gene mutants when grown in TSB or peptide rich media. Upon observation, we saw no
differences in growth for the pepT mutants as compared to the wild-type strain in either
media tested, strongly indicating these enzymes are not involved in the utilization of
peptides for growth and metabolism, as shown in S. typhimurium, E. coli, and species of
Lactococcus. These results are similar to the previously characterized PepZ
aminopeptidase enzyme, which also showed no growth impairment in TSB or 10%
skim-milk (130).
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The pepT1 and pepT2 genes are highly conserved among S. aureus isolates. BLAST
analysis performed on the protein products of these genes indicates they are part of the
M20 family of metallo-aminopeptidases, both of which contain six putative zinc metal
binding site domains, indicating these enzymes likely require zinc as a metal co-factor
for activity. According to the MEROPS peptide database, the M20 family of metallopeptidases is characterized by requiring two metal ions per enzyme monomer, and are
thus of the “co-catalytic” type. Additionally, the bacterial aminopeptidase T subfamily of
enzymes are termed tripeptidases because they are particularly known for acting upon
tripeptide substrates. However, this is not always the case, as several homologues of
the S. aureus PepT enzymes have been characterized, and are shown to be active
against a variety of substrates that differ in amino acid length. Furthermore, the PepT
homologues that have been characterized in other organisms are found to play various
roles among the cell, and have not all been linked to nutrition. For example, a pepT
gene mutant lacking a functional PepT enzyme in Lactococcus lactis showed no
differences in its growth profile compared to the wild-type strain when grown in milk
broth and casein-CDM media, indicating the enzyme is not crucial for the liberation of
essential amino acids from casein, similar to what we see for the S. aureus PepT
enzymes (180). Additionally, the PepT proteins from both E. coli and B. subtilis have
been moderately characterized and were shown to possess specificity towards
tripeptide substrates, while additional studies in E. coli have suggested a role for PepT
in glutathione degradation (181-184). However, since S. aureus does not secrete
glutathione, it is unlikely the PepT1 and PepT2 enzymes are involved in glutathione
degradation. Furthermore, in the facultative intracellular pathogen S. typhimurium, the
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PepT enzyme was found to be important in oxygen regulation, and has increased
expression during growth under anaerobic conditions, while showing no ability to cleave
tripeptide substrates under any of the conditions tested (185, 186). When investigating
the role of the S. aureus pepT mutants in response to anaerobiosis, we observed no
differences in growth as compared to the wild-type strain when exposed to anaerobic
conditions, strongly suggesting that unlike the PepT enzyme from S. typhimurium, the
S. aureus PepT enzymes play a role outside of oxygen regulation. These results are
not surprising, as S. aureus is classically considered as an extracellular pathogen, and
is infrequently exposed to anaerobic conditions (187). Overall, the characterization of S.
aureus PepT homologues in other organisms has proven their importance in general
cell physiology, however, these enzymes seem to function in different cellular pathways
than the S. aureus PepT proteins. Additionally, until this study, PepT enzymes have
never been linked to virulence, making the S. aureus PepT1 and PepT2 proteins highly
unique.

Another characteristic of PepT1 and PepT2 is that they possess putative dimerization
domains, suggesting these enzymes do not function as monomeric proteins. Typically,
monomeric structures are a characteristic of secreted aminopeptidases, while the
remaining

intracellular

aminopeptidases

display

multimeric

structures

(119).

Additionally, neither the PepT1 or PepT2 proteins were predicted to possess an Nterminal secretion signal based on SignalP analysis, strongly implying these enzymes
are not exported, and function intracellularly. This is intriguing, as the majority of
proteases linked to pathogenesis in S. aureus function as secreted virulence
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determinants (104). Thus, it became important to assess the cellular localization of the
pepT proteins, and determine if these enzymes perhaps function in a similar fashion to
the S. aureus secreted virulence factors. Western blot analysis of S. aureus secreted,
membrane, and cytoplasmic fractions determined both PepT1 and PepT2 to be
intracellular enzymes throughout all stages of growth. These results suggest that unlike
the majority of the proteases that are linked to virulence in S. aureus, the PepT
enzymes are localized to the bacterial cytoplasm, and likely contribute to pathogenesis
by the intracellular N-terminal processing of proteins involved in the overall maintenance
of cellular fitness, or pathophysiological pathways.

However, in order to fully understand the precise mechanisms and pathways by which
the PepT1 and PepT2 aminopeptidase enzymes are employed in S. aureus, it is
important to identify the exact substrate targets these proteins act upon. This was
explored by utilizing N-terminomics; a cutting edge proteomics assay designed not only
to identify differences in N-terminal peptide abundance, but to also gain insight into the
slight amino acid changes associated with N-terminal processing. Through this
approach, we identified a number of proteins with significant changes in N-terminal
peptide abundance in the pepT1 and pepT2 mutants as compared to the wild-type
strain. Remarkably, several of these proteins were identified in both the pepT mutant
strains, and had similar quantitation profiles. Most notable is an overall decrease in Nterminal peptides of ribosomal, and ribosome associated proteins in both the pepT
mutant strain proteomes. This severe decrease in ribosomal proteins likely implies the
cell is trying to cope with cellular stress and nutrient-limiting conditions by inducing the
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stringent response, which dramatically downregulates translation machinery, while
upregulating amino acid biosynthetic processes in order to increase cellular
concentrations of free amino acids (188). The fact that the pepT mutant cells are
inducing a stringent response indicates that the lack of PepT enzymes is causing
significant stress on the cell, leading to a decrease in transcription of ribosomal proteins.
Although many ribosomal proteins are essential for proper translation and overall
function of the ribosome complex as a whole, several of these proteins are dispensable,
and act primarily to improve ribosome stabilization (189). In a previous study aimed at
characterizing the prokaryotic ribosome, a majority of E. coli mutants lacking such
ribosomal proteins were still viable, and displayed no growth impairments as a result of
the loss (190). This could explain why the severe decrease in ribosomal protein
abundance does not affect the overall growth profiles of the pepT mutants.

Additionally, a universal stress protein was identified to have significantly diminished Nterminal abundance in both of the pepT mutants as compared to the wild-type strain.
Though the S. aureus universal stress proteins have not been well characterized to
date, a study analyzing the abscess proteomes from a S. aureus infection revealed a
universal stress protein, Usp2, to be enriched in kidney lesions in mice, and involved in
stringent stress response (191). In bacteria, transcriptional regulation of stress response
proteins is controlled, in part, by proteases (192). Therefore, it is reasonable to
speculate a potential role of the PepT aminopeptidases as being key regulators in a
stress response pathway.
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Of special interest, an ATP-dependent protease enzyme also known to be involved in
stress response in S. aureus, ClpC, was revealed to have drastic decreases in Nterminal peptide abundance in the pepT2 mutant as compared to the parental strain,
and was not present at all in the pepT1 mutant N-terminomic analysis. Specifically,
ClpC is a component of the ClpP proteolytic chamber, a barrel shaped structure
designed to cleave unfolded protein substrates, and is widely conserved among
bacteria (193). The role for the Clp proteases in S. aureus stress response is directed at
the degradation of non-native and unfolded proteins which have accumulated as a
result of dramatic changes in cellular conditions such as DNA damage, oxidative stress,
heightened temperatures, or the presence of antimicrobial peptides (193, 194).
Importantly, ClpP is considered to be the primary mechanism by which protein
degradation occurs in S. aureus, and largely depends on the presence of the ClpC
subunit for adequate function. In order for the protein substrate to enter the proteolytic
chamber, it must first come in contact with the ClpC ATP-ase component, which is
responsible for unfolding and translocation of the protein substrate into the active site
(195). S. aureus strains containing a deletion of the clpP gene secreted substantially
less extracellular enzymes and toxins, and resulted in severe attenuation of virulence,
while additional studies demonstrated that deletion of clpC affected the transcription of
several genes known to be involved in virulence (196-198). Additionally, in the S.
aureus strain Newman, ClpC was found to stimulate capsule formation by dampening
the expression of codY, which is postulated to be a mechanism conserved throughout
all strains (197, 199). Interestingly, CodY regulates metabolism and virulence gene
expression in S. aureus in response to nutrient availability by repressing the
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transcription of agr (200). Furthermore, a recent study revealed AgrA, which affects
expression of RNAIII, the effector molecule in Agr quorum-sensing, to be a direct
substrate target of ClpC, suggesting that ClpC plays a direct role in the regulation of
virulence in S. aureus (201). Therefore, due to the substantial role of the Clp proteases
in S. aureus virulence, the decreased abundance of N-terminal ClpC peptides in the
intracellular proteomes of the pepT mutants could certainly explain the avirulent
phenotype associated with these mutants, and suggests ClpC as a potential indirect
target of the PepT aminopeptidase enzymes.

In addition to the proteins with significant changes in N-terminal abundance found in
both pepT mutants, there were a few additional proteins of interest that were unique to
either the pepT1 or pepT2 single mutants. Specifically, a dramatic reduction of the
chaperone protein, DnaK was found in the pepT1 mutant. Previous studies in S. aureus
have shown a disruption in the dnaK gene to cause a considerably reduced ability of the
organism to survive and cause systemic infection in a mouse model, and also prove the
importance of the DnaK enzyme in stress response (202). The DnaK enzyme is
classified as a heat shock protein conserved throughout all organisms, which functions
to help deal with mis-folded and aggregated proteins that have accumulated as a result
of cellular stress, in a very similar manner as the Clp proteins (202, 203). In E. coli,
DnaK is even believed to interact with ClpB, another member of the Clp protease family,
in order to mediate the solubilization of proteins destined for ClpP processing (188).
Therefore, we speculate that the decreased abundance of N-terminal peptides from
DnaK can be attributed to the absence of the PepT1 enzyme, which likely plays a role,
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and potentially functions as a key regulator, in S. aureus stress response pathways,
which DnaK is also known to be intimately involved in. In the pepT2 mutant, we
discovered a significantly decreased abundance of ArlR, the response regulator of the
ArlRS two-component system, which is an important regulator of agglutination and
virulence in S. aureus (204). It was found that ArlRS is responsible for controlling
agglutination in S. aureus by modifying the expression of the ebh gene encoding the
Giant Staphylococcal Surface Protein, GSSP. Previous studies using an arlRS deficient
strain of S. aureus, reveled a severe inability of the mutant strain to cause disease in
both a sepsis and endocarditis infection model in rabbits, which can be in part
contributed to by the decreased agglutination of the arlRS mutant strain (204). Our
results indicate a potential interaction of the PepT2 enzyme in the ArlRS regulation
pathways of virulence and pathogenesis in S. aureus, and could explain the virulence
phenotypes we are seeing with the pepT2 mutant strain.

S. aureus is an opportunistic pathogen, which is highly prevalent among humans, and is
the leading cause of skin and soft tissue infections, while also causing a plethora of
severe diseases, such as endocarditis, toxic shock syndrome, pneumonia, and
osteomyelitis (20, 21). The extended pathogenicity of S. aureus is largely the result of
its repertoire of virulence factors, which allow the bacterium to invade, adhere to, and
disseminate throughout host tissues and the bloodstream. Virulence determinants of S.
aureus include various secreted toxins, hemolysins, nucleases, proteases, and
adhesins (67). In this study, we identified two M20 family metallo-aminopeptidases,
PepT1 and PepT2, necessary for full S. aureus pathogenesis, which don’t seem to play
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a major role in nutrition and metabolism. Our results demonstrate a decreased fitness of
the pepT mutant strains in both ex vivo human, and in vivo animal models of infection,
suggesting the lack of these enzymes causes severe cellular stress. Analysis of several
proteins identified with altered N-terminal peptide abundance, which are potentially
direct targets of PepT1 and PepT2, indicate these enzymes are likely involved overall
bacterial

stress

response

and

virulence,

and

function

through

the

bioactivation/inactivation of secondary proteins, which are tightly involved in these
stress response, and virulence pathways.
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Future Directions

In order to elucidate further the exact roles of the S. aureus PepT1 and PepT2
enzymes, it would be advantageous to explore the specific interactions these enzymes
have with the proteins that were identified during the N-terminomics experiment to have
significant changes in N-terminal peptide abundance. Due to the abundance of proteins
identified in virulence and cellular stress response, there is a large potential that these
enzymes function in the bioactivation or inactivation of key proteins involved in these
pathways. In order to correlate the changes in N-terminal peptide abundance seen to
changes in intracellular protein abundance, it would be beneficial to perform iTRAQ
analysis on the pepT mutants. Of special interest, we aim to explore the specific role of
the PepT enzymes in relation to the ClpC ATP-ase by creating a pepT1/pepT2/clpC
triple mutant, followed by subsequent phenotypic analysis, in order to determine the
overall cellular effect of the loss of all three enzymes. These results could potentially
give insight into the cooperation of the PepT enzymes with the ClpC proteases during S.
aureus infection and stress response. Additionally exploring the amino acid preference
and specificity of the PepT enzymes will help to identify other potential substrate targets
within the cell, since it has previously been shown that these enzymes can have
functions independent of their aminopeptidase activity.
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The PepT1 and PepT2 Enzyme Mutants Are Not Essential for Growth in Amino
Acid Limiting Media.
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Figure A-1. The PepT1 and PepT2 Enzyme Mutants Are Not Essential for Growth
in Amino Acid Limiting Media. Exponentially growing wild-type, pepT1 and pepT2
mutant strains were separately inoculated, in triplicate, in CDM, an amino acid limiting
media. Cultures were allowed to grow for 7 days. Samples were taken daily, serially
diluted, and plated on TSA. Shown above are two independent experiments (A, B).
Percent survival was determined by calculating CFU/mL compared to the inoculum. No
bacteria were recovered after 4 days at 37o C with shaking. Error bars are shown ±SEM.
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The pepT1 and pepT2 Mutants Do Not Display Altered Membrane Integrity.
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Figure A-2. The pepT1 and pepT2 Mutants Do Not Display Altered Membrane
Integrity . Exponentially growing wild-type, pepT1 and pepT2 mutant strains were
exposed, in triplicate, to the addition of 1.5% toluene (A), and 0.01% oleic acid (B), and
allowed to grow for 1 h at 37oC with shaking. Samples were taken every 15 minutes,
serially diluted, and plated in duplicate on TSA. Percent survival was determined by
calculating CFU/mL compared to the inoculum. Error bars are shown ±SEM.
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Assaying pepT1/T2 in Response to Autolysis.
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Figure A-3. Assaying pepT1/T2 in Response to Autolysis. Exponentially growing
cultures of wild-type and pepT1/T2 strains were standardized to an OD600 of 0.5, and
allowed to reach an OD600 of 1.5. Cells were then pelleted, washed three times with
sterile PBS buffer, and re-suspended in sterile PBS buffer containing 1.5% Triton X-100.
Cultures were incubated at 37oC with shaking, and the ODs measured every 20 min for
a total of 140 min, with a final measurement at 24 h. Experiment was performed in
triplicate, and ODs measured in duplicate. Percent survival was determined by the
OD600 of each time point as compared to the initial OD600 measurement. Significance
was determined using a student’s t-test ( * ,p < 0.05), error bars are shown ±SEM.
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Response of the pepT Mutants to Anaerobiosis.
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Figure A-4. Response of the pepT Mutants to Anaerobiosis. Exponentially growing
wild-type, pepT1, pepT2, and pepT1/T2 double mutant strains were separately
inoculated, in triplicate, in TSB. Cultures were grown anaerobically for 24 h at 37oC with
shaking (A), as well as 37oC statically (B). Samples were taken at 0 h, 3 h, 6 h, 9 h, and
24 h, serially diluted, and plated on TSA. Percent survival was determined by
calculating CFU/mL compared to the inoculum. Error bars are shown ±SEM.
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Proteins Identified From N-Terminomics Analysis.

Table A-1. Proteins Identified From N-Terminomics Analysis
#

Identified Proteins (349)

Accession #

1

Pur operon repressor

Q2FJE6_STAA3

Mol.
Weight
30 kDa

2

50S ribosomal protein L2

RL2_STAA3

30 kDa

3

ATP-dependent Clp protease ATP-binding subunit ClpC

CLPC_STAA3

91 kDa

4

AANH-like and USP-like superfamily; universal stress protein

Q2FG32_STAA3

15 kDa

5

50S ribosomal protein L17

RL17_STAA3

14 kDa

6

Dihydrofolate reductase

Q2FH12_STAA3

18 kDa

7

50S ribosomal protein L16

RL16_STAA3

16 kDa

8

Bifunctional purine biosynthesis protein PurH

PUR9_STAA3

54 kDa

9

UPF0435 protein

Y1861_STAA3

8 kDa

10

Chaperone protein DnaK

DNAK_STAA3

66 kDa

11

Heme oxygenase (staphylobilin-producing)

HDOX2_STAA3

13 kDa

12

Thioredoxin

THIO_STAA3

11 kDa

13

Phosphoglycerate kinase

PGK_STAA3

43 kDa

14

Malonyl CoA-acyl carrier protein transacylase

Q2FHK8_STAA3

34 kDa

15

50S ribosomal protein L5

RL5_STAA3

20 kDa

16

Response regulator ArlR

ARLR_STAA3

25 kDa

17

Inositol monophosphatase family protein

Q2FHX3_STAA3

30 kDa

18

Probable glycine dehydrogenase (decarboxylating) subunit 2

GCSPB_STAA3

55 kDa

19

50S ribosomal protein L6

RL6_STAA3

20 kDa

20

Phosphate acetyltransferase

Q2FJ55_STAA3

35 kDa

21

Phi77 ORF011-like protein, phage transcriptional repressor

Q2FFA8_STAA3

27 kDa

22

Cytidine deaminase

Q2FGF5_STAA3

15 kDa

23

HTH-type transcriptional regulator SarR

SARR_STAA3

14 kDa

24

50S ribosomal protein L22

RL22_STAA3

13 kDa

25

Putative pyridoxal phosphate-dependent acyltransferase

Q2FJ90_STAA3

43 kDa

26

Polyribonucleotide nucleotidyltransferase

Q2FJD3_STAA3

15 kDa

27

30S ribosomal protein S5

RS5_STAA3

18 kDa

28

Glycerol kinase

GLPK_STAA3

56 kDa

29

Uncharacterized protein

Q2FHC5_STAA3

10 kDa

30

Phosphoribosylformylglycinamidine synthase

Q2FI11_STAA3

10 kDa

31

Ribose-phosphate pyrophosphokinase

Q2FJE1_STAA3

35 kDa

32

Glycine betaine aldehyde dehydrogenase

Q2FDP8_STAA3

55 kDa

33

ATP-dependent zinc metalloprotease FtsH

Q2FJD0_STAA3

78 kDa
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34

30S ribosomal protein S7

RS7_STAA3

18 kDa

35

50S ribosomal protein L11

RL11_STAA3

15 kDa

36

Hydroxymethylglutaryl-CoA reductase

Q2FDW1_STAA3

46 kDa

37

50S ribosomal protein L10

RL10_STAA3

18 kDa

38

30S ribosomal protein S1

Q2FGW6_STAA3

43 kDa

39

Glucosamine-6-phosphate isomerase

Q2FFP1_STAA3

22 kDa

40

30S ribosomal protein S3

RS3_STAA3

24 kDa

41

Thioredoxin reductase

Q2FIM9_STAA3

34 kDa

42

Alanine dehydrogenase

DHA1_STAA3

40 kDa

43

Purine nucleoside phosphorylase DeoD-type

Q2FEZ1_STAA3

26 kDa

44

Probable malate:quinone oxidoreductase

Q2FDQ3_STAA3

56 kDa

45

Glycine betaine/carnitine/choline ABC transporter

Q2FE52_STAA3

35 kDa

46

Uncharacterized protein

Q2FFL3_STAA3

10 kDa

47

D-isomer specific 2-hydroxyacid dehydrogenase family protein

Q2FFN3_STAA3

36 kDa

48

Uncharacterized protein

Q2FGA2_STAA3

6 kDa

49

Transferrin receptor

Q2FIQ4_STAA3

38 kDa

50

Uncharacterized protein

Q2FIV7_STAA3

27 kDa

51

50S ribosomal protein L27

RL27_STAA3

10 kDa

52

30S ribosomal protein S8

RS8_STAA3

15 kDa

53

Putative serine protease HtrA

Q2FG10_STAA3

46 kDa

54

50S ribosomal protein L13

RL13_STAA3

16 kDa

55

Regulatory protein Spx

Q2FI80_STAA3

15 kDa

56

Uncharacterized protein

Q2FEU8_STAA3

21 kDa

57

30S ribosomal protein S11

RS11_STAA3

14 kDa

58

Alcohol dehydrogenase

ADH_STAA3

36 kDa

59

30S ribosomal protein S20

RS20_STAA3

9 kDa

60

Dihydroorotase

Q2FHN7_STAA3

46 kDa

61

NADH dehydrogenase-like protein

Y844_STAA3

44 kDa

62

Elongation factor G

EFG_STAA3

77 kDa

63

Glyceraldehyde-3-phosphate dehydrogenase, type I

Q2FIM1_STAA3

36 kDa

64

50S ribosomal protein L15

RL15_STAA3

16 kDa

65

Methionine aminopeptidase

Q2FFK7_STAA3

28 kDa

66

Catabolite control protein A

Q2FG02_STAA3

36 kDa

67

D-isomer specific 2-hydroxyacid dehydrogenase

Q2FIE4_STAA3

35 kDa

68

Uncharacterized protein

Q2FE90_STAA3

9 kDa

69

DNA-directed RNA polymerase subunit beta

RPOB_STAA3

133kDa

70

Uncharacterized protein

Q2FJM9_STAA3

15 kDa

71

30S ribosomal protein S13

RS13_STAA3

14 kDa
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72

2,3-bisphosphoglycerate-dependent phosphoglycerate mutase

GPMA_STAA3

27 kDa

73

Staphylococcal respiratory response protein, SrrA

Q2FGP0_STAA3

28 kDa

74

Peptidase T

PEPT_STAA3

46 kDa

75

Glutamine—fructose-6-phosphate aminotransferase

Q2FEX8_STAA3

66 kDa

76

Uncharacterized hydrolase

Y2518_STAA3

31 kDa

77

2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase

ISPD_STAA3

27 kDa

78

Elongation factor P

EFP_STAA3

21 kDa

79

Putative endoribonuclease L-PSP

Q2FJE5_STAA3

14 kDa

80

UPF0291 protein

Q2FH93_STAA3

9 kDa

81

Uncharacterized protein

Q2FH59_STAA3

18 kDa

82

Fructose-bisphosphate aldolase class 1

ALF1_STAA3

33 kDa

83

Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit C

GATC_STAA3

11 kDa

84

Uncharacterized protein

Q2FGH7_STAA3

12 kDa

85

HPr kinase/phosphorylase

HPRK_STAA3

34 kDa

86

Uncharacterized protein

Q2FH08_STAA3

9 kDa

87

Low molecular weight protein-tyrosine-phosphatase PtpA

PTPA_STAA3

17 kDa

88

Uncharacterized protein

Q2FFL9_STAA3

6 kDa

89

Putative tRNA (cytidine(34)-2’-O)-methyltransferase

Q2FFP0_STAA3

18 kDa

90

Q2FK91_STAA3

19 kDa

91

DUF4242 superfamily;
dipeptide/oligopeptide/nickel ABC transporter permease
Glyoxalase family protein

Q2FGM4_STAA3

14 kDa

92

Transcription elongation factor GreA

GREA_STAA3

18 kDa

93

Uncharacterized protein

Q2FJN1_STAA3

36 kDa

94

Oxidoreductase, short chain dehydrogenase/reductase family

Q2FEG8_STAA3

32 kDa

95

ATP synthase subunit alpha

ATPA_STAA3

55 kDa

96

Glycine—tRNA ligase

SYG_STAA3

54 kDa

97

50S ribosomal protein L32

RL32_STAA3

6 kDa

98

Formate acetyltransferase

PFLB_STAA3

85 kDa

99

Uncharacterized protein

Q2FFY6_STAA3

16 kDa

100

50S ribosomal protein L7/L12

RL7_STAA3

13 kDa

101

50S ribosomal protein L30

RL30_STAA3

7 kDa

102

Universal stress protein family

Q2FKJ2_STAA3

17 kDa

103

Cysteine—tRNA ligase

SYC_STAA3

54 kDa

104

Transcriptional regulator MraZ

MRAZ_STAA3

17 kDa

105

Peptide deformylase

Q2FHY9_STAA3

21 kDa

106

Single-stranded DNA-binding protein

Q2FJP7_STAA3

19 kDa

107

Uncharacterized protein

Y736_STAA3

22 kDa

108

Protein GrpE

GRPE_STAA3

24 kDa
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109

Uncharacterized protein

Q2FFG7_STAA3

22 kDa

110

Urease accessory protein UreG

UREG_STAA3

22 kDa

111

Glutamine amidotransferase subunit PdxT

PDXT_STAA3

21 kDa

112

Proline—tRNA ligase

SYP_STAA3

64 kDa

113

6,7-dimethyl-8-ribityllumazine synthase

RISB_STAA3

16 kDa

114

Glyceraldehyde-3-phosphate dehydrogenase, type I

Q2FG50_STAA3

37 kDa

115

Nucleoside diphosphate kinase

NDK_STAA3

17 kDa

116

50S ribosomal protein L19

RL19_STAA3

13 kDa

117

3-hexulose-6-phosphate synthase

HPS_STAA3

22 kDa

118

Acetyltransferase, GNAT family

Q2FEZ9_STAA3

33 kDa

119

Putative formate dehydrogenase

FDHL_STAA3

111 kDa

120

Clumping factor A

Q2FIK6_STAA3

97 kDa

121

Glutamate racemase

MURI_STAA3

30 kDa

122

Translation initiation factor IF-2

IF2_STAA3

78 kDa

123

Uncharacterized protein

Q2FG26_STAA3

36 kDa

124

Uncharacterized protein

Q2FII5_STAA3

34 kDa

125

DNA-directed RNA polymerase subunit beta’

RPOC_STAA3

135 kDa

126

ATP-dependent DNA helicase, PcrA

Q2FFJ0_STAA3

84 kDa

127

Penicillin-binding protein 1

Q2FHQ6_STAA3

83 kDa

128

Uncharacterized protein

Q2FDR5_STAA3

17 kDa

129

Uncharacterized protein

Q2FIW1_STAA3

11 kDa

130

Molecular chaperone Hsp31 and 144lyoxalase 3

HCHA_STAA3

32 kDa

131

UPF0365 protein

Y1533_STAA3

35 kDa

132

Peptide methionine sulfoxide reductase MsrA

Q2FH14_STAA3

21 kDa

133

Uncharacterized protein

Q2FGY0_STAA3

25 kDa

134

Anti-sigma factor antagonist

Q2FF58_STAA3

12 kDa

135

Hydrolase, TatD family

Q2FJF1_STAA3

29 kDa

136

Protein ArsC

ARSC_STAA3

15 kDa

137

N utilization substance protein B homolog

NUSB_STAA3

15 kDa

138

NH(3)-dependent NAD(+) synthetase

NADE_STAA3

31 kDa

139

Putative pyruvate, phosphate dikinase regulatory protein

PDRP_STAA3

31 kDa

140

RNA methyltransferase, TrmH family, group 3

Q2FJA8_STAA3

27 kDa

141

Transaldolase

Q2FFW0_STAA3

26 kDa

142

Antibacterial protein

Q2FHR4_STAA3

4 kDa

143

Uncharacterized protein

Q2FHZ8_STAA3

20 kDa

144

Putative glycerophosphoryl diester phosphodiesterase

Q2FKM8_STAA3

28 kDa

145

Threonine—tRNA ligase

SYT_STAA3

74 kDa

146

Protein translocase subunit SecA 1

SECA1_STAA3

96 kDa

144

Table A-1. (Continued)

	
  

147

Uncharacterized protein

Q2FGJ4_STAA3

12 kDa

148

30S ribosomal protein S14 type Z

RS14Z_STAA3

7 kDa

149

Uncharacterized protein

Q2FDS2_STAA3

12 kDa

150

Xanthine phosphoribosyltransferase

XPT_STAA3

21 kDa

151

Molybdenum cofactor biosynthesis protein B

Q2FEL7_STAA3

18 kDa

152

Uncharacterized protein

Q2FGY1_STAA3

12 kDa

153

ATP-dependent protease ATPase subunit HslU

HSLU_STAA3

52 kDa

154

Serine-protein kinase RsbW

RSBW_STAA3

18 kDa

155

Pyruvate dehydrogenase E1 component, beta subunit

Q2FHY6_STAA3

35 kDa

156

Uncharacterized protein

Q2FFM0_STAA3

19 kDa

157

Putative 2-hydroxyacid dehydrogenase

Y2254_STAA3

35 kDa

158

Probable endonuclease 4

END4_STAA3

33 kDa

159

CON__P08779

CON__P08779

?

160

Glutamyl-aminopeptidase

Q2FE43_STAA3

39 kDa

161

Uncharacterized protein

Q2FF40_STAA3

8 kDa

162

50S ribosomal protein L29

Q2FEP7_STAA3

9 kDa

163

Veg protein

Q2FJE8_STAA3

10 kDa

164

Succinyl-CoA ligase [ADP-forming] subunit beta

SUCC_STAA3

42 kDa

165

DNA-binding protein HU

Q2FGW9_STAA3

10 kDa

166

Translation initiation factor IF-1

IF1_STAA3

8 kDa

167

Lysine—tRNA ligase

SYK_STAA3

57 kDa

168

Mannitol-1-phosphate 5-dehydrogenase

MTLD_STAA3

41 kDa

169

Phosphoenolpyruvate-protein phosphotransferase

Q2FHZ6_STAA3

63 kDa

170

Mannose-6-phosphate isomerase, class I

Q2FDL7_STAA3

35 kDa

171

UPF0337 protein

Y816_STAA3

7 kDa

172

Phosphoglucosamine mutase

GLMM_STAA3

49 kDa

173

DNA-directed RNA polymerase subunit omega

RPOZ_STAA3

8 kDa

174

Alcohol dehydrogenase, zinc-containing

Q2FK14_STAA3

38 kDa

175

UPF0457 protein

Y2132_STAA3

10 kDa

176

Galactose-6-phosphate isomerase subunit LacA

LACA_STAA3

15 kDa

177

S-ribosylhomocysteine lyase

LUXS_STAA3

18 kDa

178

Dihydrolipoyl dehydrogenase

Q2FHY4_STAA3

49 kDa

179

Uncharacterized protein

Q2FE41_STAA3

10 kDa

180

PTS system EIIBC component

PTXBC_STAA3

51 kDa

181

DNA topoisomerase 4 subunit A

Q2FH80_STAA3

91 kDa

182

HIT family protein

Q2FFQ8_STAA3

16 kDa

183

Dihydroxyacetone kinase, DhaL subunit

Q2FIY8_STAA3

21 kDa

184

Alkyl hydroperoxide reductase subunit C

AHPC_STAA3

21 kDa
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185

Acetyl-CoA carboxylase, biotin carboxyl carrier protein

Q2FGB9_STAA3

17 kDa

186

Phenol-soluble modulin alpha 4 peptide

PSMA4_STAA3

2 kDa

187

Triosephosphate isomerase

TPIS_STAA3

27 kDa

188

Transcription termination factor NusA

Q2FHH2_STAA3

44 kDa

189

Uncharacterized protein

Q2FK92_STAA3

8 kDa

190

Uncharacterized protein

Q2FKN1_STAA3

49 kDa

191

Uncharacterized protein

Q2FEB6_STAA3

16 kDa

192

Transcription termination/antitermination protein NusG

Q2FJA4_STAA3

21 kDa

193

Branched-chain-amino-acid aminotransferase

Q2FJ86_STAA3

40 kDa

194

Putative NADP-dependent malic enzyme

Q2FG36_STAA3

44 kDa

195

Potassium uptake protein

Q2FHZ2_STAA3

24 kDa

196

Uncharacterized protein

Q2FID7_STAA3

39 kDa

197

Probable DNA-directed RNA polymerase subunit delta

RPOE_STAA3

21 kDa

198

30S ribosomal protein S4

RS4_STAA3

23 kDa

199

Uncharacterized protein

Q2FI49_STAA3

7 kDa

200

Citrate synthase

Q2FG42_STAA3

43 kDa

201

30S ribosomal protein S16

RS16_STAA3

10 kDa

202

Aspartate-semialdehyde dehydrogenase1

Q2FH44_STAA3

36 kDa

203

30S ribosomal protein S18

RS18_STAA3

9 kDa

204

Tyrosine—tRNA ligase

SYY_STAA3

48 kDa

205

Uncharacterized protein

Q2FEN1_STAA3

6 kDa

206

Putative cell-division initiation protein

Q2FHP5_STAA3

24 kDa

207

30S ribosomal protein S6

RS6_STAA3

12 kDa

208

Uknown_Protein_13398

?

?

209

Rhodanese-like domain protein

Q2FFY1_STAA3

11 kDa

210

Succinyl-CoA ligase [ADP-forming] subunit alpha

Q2FHJ2_STAA3

32 kDa

211

D-alanine—poly(phosphoribitol) ligase subunit 1

DLTA_STAA3

55 kDa

212

Putative thioredoxin

Q2FII9_STAA3

12 kDa

213

Probable thiol peroxidase

Q2FG25_STAA3

18 kDa

214

60 kDa chaperonin

CH60_STAA3

58 kDa

215

50S ribosomal protein L31 type B

RL31B_STAA3

10 kDa

216

50S ribosomal protein L14

RL14_STAA3

13 kDa

217

Putative sporulation transcription regulator WhiA

WHIA_STAA3

36 kDa

218

GTP cyclohydrolase FolE2

GCH4_STAA3

33 kDa

219

2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-acetyltransferase

DAPH_STAA3

25 kDa

220

30S ribosomal protein S2

RS2_STAA3

29 kDa

221

Phenol-soluble modulin alpha 1 peptide

PSMA1_STAA3

2 kDa

222

Serine—tRNA ligase

SYS_STAA3

49 kDa
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223

Uracil phosphoribosyltransferase

UPP_STAA3

23 kDa

224

Methylenetetrahydrofolate—tRNA-(uracil-5-)-methyltransferase TrmFO

TRMFO_STAA3

48 kDa

225

Phosphoribosylaminoimidazole-succinocarboxamide synthase

PUR7_STAA3

27 kDa

226

UPF0477 protein

Y916_STAA3

19 kDa

227

Uncharacterized protein

Q2FFQ7_STAA3

13 kDa

228

Dihydrolipoamide acetyltransferase

Q2FHY5_STAA3

46 kDa

229

50S ribosomal protein L4

RL4_STAA3

22 kDa

230

Putative septation protein SpoVG

SP5G_STAA3

11 kDa

231

Fructose bisphosphate aldolase

Q2FF03_STAA3

31 kDa

232

NADH-dependent FMN reductase

Q2FJS4_STAA3

21 kDa

233

50S ribosomal protein L23

RL23_STAA3

11 kDa

234

UPF0741 protein

Y575_STAA3

14 kDa

235

Phosphoribosylformylglycinamidine synthase 2

PURL_STAA3

80 kDa

236

50S ribosomal protein L28

RL28_STAA3

7 kDa

237

DNA polymerase III subunit beta

Q2FKQ4_STAA3

42 kDa

238

50S ribosomal protein L25

RL25_STAA3

24 kDa

239

UPF0403 protein

Y1321_STAA3

16 kDa

240

Copper chaperone CopZ

COPZ_STAA3

7 kDa

241

Probable uridylyltransferase

URTF_STAA3

45 kDa

242

Delta-hemolysin

Q2FF89_STAA3

5 kDa

243

Ornithine aminotransferase

Q2FIB8_STAA3

43 kDa

244

Putative acyl-CoA acetyltransferase FadA

Q2FK39_STAA3

42 kDa

245

UPF0122 protein

Y1129_STAA3

14 kDa

246

Cell cycle protein GpsB

GPSB_STAA3

13 kDa

247

UPF0342 protein

Y1795_STAA3

13 kDa

248

Putative oxidoreductase

Q2FJT5_STAA3

38 kDa

249

Imidazolonepropionase

HUTI_STAA3

45 kDa

250

Guanylate kinase

KGUA_STAA3

24 kDa

251

30S ribosomal protein S15

RS15_STAA3

11 kDa

252

Elongation factor Tu

EFTU_STAA3

43 kDa

253

MutT/nudix family protein

Q2FG59_STAA3

23 kDa

254

GTP-sensing transcriptional pleiotropic repressor CodY

CODY_STAA3

29 kDa

255

Putative dipeptidase

PEPVL_STAA3

53 kDa

256

30S ribosomal protein S10

RS10_STAA3

12 kDa

257

Serine hydroxymethyltransferase

GLYA_STAA3

45 kDa

258

1-pyrroline-5-carboxylate dehydrogenase

ROCA_STAA3

57 kDa

259

MutT/nudix family protein

Q2FGN3_STAA3

20 kDa

260

Methylated DNA-protein cysteine methyltransferase

Q2FDV9_STAA3

19 kDa
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261

Putative peptidyl-prolyl cis-trans isomerase

PPI1_STAA3

22 kDa

262

L-lactate dehydrogenase 1

LDH1_STAA3

35 kDa

263

Uncharacterized protein

Q2FJF9_STAA3

12 kDa

264

Putative lipoprotein

Q2FJP2_STAA3

21 kDa

265

50S ribosomal protein L35

RL35_STAA3

8 kDa

266

Uncharacterized protein

Q2FG19_STAA3

17 kDa

267

Putative thioredoxin

Q2FFZ4_STAA3

12 kDa

268

Thymidylate kinase

KTHY_STAA3

23 kDa

269

Hydroxymethylglutaryl-CoA synthase

Q2FDW0_STAA3

43 kDa

270

Putative NAD(P)H nitroreductase

Y2462_STAA3

25 kDa

271

50S ribosomal protein L21

RL21_STAA3

11 kDa

272

Translation initiation factor IF-3

IF3_STAA3

20 kDa

273

Phosphocarrier protein HPr

Q2FHZ7_STAA3

9 kDa

274

33 kDa chaperonin

HSLO_STAA3

32 kDa

275

Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha

ACCA_STAA3

35 kDa

276

Phenylalanyl-tRNA synthetase (Beta subunit)

Q2FFZ6_STAA3

22 kDa

277

Cold shock protein CspA

CSPA_STAA3

7 kDa

278

Acetoin(Diacetyl) reductase

Q2FKD2_STAA3

27 kDa

279

Nitroreductase family protein

Q2FIJ0_STAA3

21 kDa

280

4-oxalocrotonate tautomerase

Q2FH73_STAA3

7 kDa

281

30S ribosomal protein S19

RS19_STAA3

11 kDa

282

Uncharacterized protein

Q2FID9_STAA3

9 kDa

283

Probable manganese-dependent inorganic pyrophosphatase

PPAC_STAA3

34 kDa

284

Superoxide dismutase [Mn/Fe] 2

SODM2_STAA3

23 kDa

285

30S ribosomal protein S9

RS9_STAA3

15 kDa

286

SUF system FeS assembly protein, NifU family

Q2FIF7_STAA3

17 kDa

287

Organic hydroperoxide resistance protein-like

OHRL_STAA3

15 kDa

288

Elastin-binding protein EbpS

EBPS_STAA3

53 kDa

289

Acyl carrier protein

ACP_STAA3

9 kDa

290

Ribosome-binding ATPase YchF

Q2FJQ0_STAA3

41 kDa

291

D-alanine—poly(phosphoribitol) ligase subunit 2

DLTC_STAA3

9 kDa

292

2,3-bisphosphoglycerate-independent phosphoglycerate mutase

Q2FIL8_STAA3

56 kDa

293

D-lactate dehydrogenase

Q2FDY1_STAA3

39 kDa

294

Uncharacterized protein

Q2FHE7_STAA3

11 kDa

295

Aerobic glycerol-3-phosphate dehydrogenase

GLPD_STAA3

62 kDa

296

Lantibiotic epidermin immunity protein F

Q2FFS5_STAA3

26 kDa

297

UPF0337 protein

Y1582_STAA3

7 kDa

298

6-phosphogluconate dehydrogenase, decarboxylating

Q2FGM3_STAA3

52 kDa
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299

Putative Holliday junction resolvase

RUVX_STAA3

16 kDa

300

Iron-sulfur cluster repair protein ScdA

SCDA_STAA3

25 kDa

301

Arginase

Q2FEW8_STAA3

33 kDa

302

Pyridoxal biosynthesis lyase PdxS

PDXS_STAA3

32 kDa

303

30S ribosomal protein S12

RS12_STAA3

15 kDa

304

Cell division protein FtsZ

Q2FHQ1_STAA3

41 kDa

305

Maltose operon transcriptional repressor

Q2FGM5_STAA3

38 kDa

306

50S ribosomal protein L18

RL18_STAA3

13 kDa

307

10 kDa chaperonin

CH10_STAA3

10 kDa

308

Alkaline shock protein 23

ASP23_STAA3

19 kDa

309

Trigger factor

TIG_STAA3

49 kDa

310

2-oxoisovalerate dehydrogenase, E1 component, beta subunit

Q2FGL7_STAA3

36 kDa

311

Inosine-5’-monophosphate dehydrogenase

IMDH_STAA3

53 kDa

312

DNA-directed RNA polymerase subunit alpha

RPOA_STAA3

35 kDa

313

Phosphoribosylformylglycinamidine cyclo-ligase

PUR5_STAA3

37 kDa

314

Cysteine synthase

Q2FJC8_STAA3

33 kDa

315

Putative universal stress protein

Y1656_STAA3

18 kDa

316

50S ribosomal protein L20

RL20_STAA3

14 kDa

317

UPF0356 protein

Y990_STAA3

9 kDa

318

Deoxyribose-phosphate aldolase

Q2FEZ2_STAA3

23 kDa

319

50S ribosomal protein L3

RL3_STAA3

24 kDa

320

Enolase

ENO_STAA3

47 kDa

321

Uncharacterized protein

Q2FJY6_STAA3

11 kDa

322

Transcriptional regulator SarA

SARA_STAA3

15 kDa

323

Ribosome-recycling factor

RRF_STAA3

20 kDa

324

ATP-dependent Clp protease proteolytic subunit

CLPP_STAA3

22 kDa

325

Uncharacterized protein

Q2FHV4_STAA3

21 kDa

326

3-oxoacyl-(Acyl-carrier-protein) reductase

Q2FHK7_STAA3

26 kDa

327

UDP-N-acetylglucosamine 1-carboxyvinyltransferase

Q2FF04_STAA3

45 kDa

328

ATP-dependent Clp protease ATP-binding subunit ClpL

CLPL_STAA3

78 kDa

329

Adenylate kinase

Q2FER0_STAA3

24 kDa

330

Glycine cleavage system H protein

GCSH_STAA3

14 kDa

331

50S ribosomal protein L9

RL9_STAA3

16 kDa

332

ABC transporter, ATP-binding protein

Q2FH46_STAA3

60 kDa

333

Uncharacterized protein

Q2FJP1_STAA3

11 kDa

334

CamS sex pheromone cAM373

Q2FFJ2_STAA3

45 kDa

335

ATP synthase subunit beta

ATPB_STAA3

51 kDa

336

Pyruvate kinase

KPYK_STAA3

63 kDa

149

Table A-1. (Continued)

	
  

337

Elongation factor Ts

EFTS_STAA3

32 kDa

338

Alkyl hydroperoxide reductase, subunit F

Q2FJN5_STAA3

55 kDa

339

Bifunctional protein FolD

FOLD_STAA3

31 kDa

340

30S ribosomal protein S21

RS21_STAA3

7 kDa

341

Putative arsenate reductase

Q2FII8_STAA3

14 kDa

342

Pyruvate dehydrogenase E1 component, alpha subunit

Q2FHY7_STAA3

41 kDa

343

Hydroxyethylthiazole kinase

THIM_STAA3

28 kDa

344

Nucleoid-associated protein

Y453_STAA3

12 kDa

*Listed are the HPLC-MS/MS identified proteins from the N-terminomic analysis of the
wild-type, pepT1, and pepT2 mutant intracellular proteomes. Protein data-sets were
validated by searching against a known S. aureus protein database. Accession
numbers correspond to the GenBank protein accession numbers located in the National
Center for Biotechnology Information (NCBI).
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